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Abstract 
 
 
The work presented in this thesis explores the use of electrohydrodynamic 
atomisation as a one-step method for the fabrication of monodispersed 
poly(lactic acid) and poly(lactic-co-glycolic) nanoparticles designed for 
selective delivery of anti-cancer drugs.  
 
Following optimisation studies of the relevant electrospray parameters, a 
range of PLA and PLGA nanocarriers loaded with the anti-cancer drug 
doxorubicin and with folic acid (aimed at achieving tumour targeting) was 
prepared and characterised using dynamic light scattering, electrophoretic 
mobility measurements, and confocal and atomic force microscopy. Unloaded 
and/or selectively loaded nanoparticles were also fabricated using the same 
technique and employed as controls. It was found - for all nanoparticles tested 
- that sensible yield, minimal size and polydispersity were obtained when 
using dimethylsulphoxide and dichloromethane with an optimal collection 
distance of 15 cm, applied voltage 9.2 – 9.6 kV and flow rate 10 µL/min.  
 
Nanoparticles were further tested in vitro for their interactions with human 
cells in terms of toxicity, tumour selectivity and cellular uptake, by using a 
range of techniques that include cytotoxicity assays, confocal microscopy, 
live-cell imaging and flow cytometry. When compared to the results obtained 
with normal human cells (16HBE), those attained using human cancer cells 
that overexpress folate receptors (CALU-3) indicated an increased cytotoxic 
effect of the loaded nanoparticles. Furthermore, cellular uptake studies 
demonstrated significant selectivity of the nanoparticles loaded with both 
doxorubicin and folic acid for the CALU-3 cell line compared to normal 
16HBE cells.  ii	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1. Literature background 
 
1.1. Nanocarriers as drug delivery systems 
 
Nanomaterials are used widely in the field of medicine due to their ability to improve drug 
efficacy and safety during delivery; they are defined by The International Organisation for 
Standardisation (ISO) as a ‘material with any external dimension in the nanoscale or 
having internal structure or surface structure in the nanoscale’.1 
 
Some of the fundamental features nanomaterials possess that make them ideal for medical 
applications include: small size that allowing integration into cellular processes, large 
surface area for a high capacity of active, high stability improves distance of action and the 
protection of ‘sensitive’ payloads, with the possibility of targeted action resulting in 
decreased toxicity and increased bioavailability. Nanomaterials already approved for use in 
medicine (nanomedicines) by the Food and Drug Administration (FDA) include: Doxil®, 
Abraxane® and Estrasorb®.2  
 
 
 
Figure 1.1. Schematic representation of main nanocarrier types (adapted from ref. 3–5)  
  
= Lipophilic drugs 
Hydrophilic head 
Hydrophobic tail 
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Nanoparticles, defined in this work as solid core spherical particulates having their main 
dimension in the nanometre range, have been studied extensively as carrier systems for the 
improved delivery of chemotherapeutic agents. In common with other nano-scale drug 
delivery systems (Figure 1.1), these may be capable of imparting targeting specificity and 
controlled release properties to their therapeutic load.6,7 
 
Appropriate molecular design may bestow to, nanocarriers. drug-delivery properties that 
include: the capability to pass through capillary vessels and consequently avoid rapid 
clearance by phagocytosis; prolonged residence time in the bloodstream; biodegradability; 
stimulus (temperature, pH, oxidative state) responsivity; the capability to penetrate cells 
and tissues; and improved effectiveness through the controlled release and reduced side 
effects of incorporated actives.4,5,8 Towards these goals, many types of nanocarrier systems 
have been developed according to the demands of each therapeutic application.  
 
Nanocapsules are nano-vesicular systems in which a reservoir containing a drug is 
entrapped within a shell/coating, which most commonly is a membrane of polymeric 
nature.9 Dependent upon its hydrophilicity, the incorporated drug may be solid, liquid, or 
in solution or dispersion.10–14 Micelles have a hydrophilic shell structure that allows them 
to remain stealthy in blood circulation; nano-sized micelles mimic aspects of the biological 
transport system in that they are not normally amenable to uptake by the 
reticuloendothelial system.15 
 
Nanoliposomes are vesicles in which the phospholipid membrane is surrounded by an 
aqueous layer (Figure 1.1). Many phospholipids occur naturally as constituents of 
biological membranes.16–18 They consist of a hydrophobic ‘fatty acid’ tail and hydrophobic 
‘phosphate group’ head. The use of liposomal carrier systems in drug delivery has been 
rationalised in terms of their capability to transport both lipophilic drugs and hydrophilic 
drugs.19 
 
Dendrimers are hyper-branched macromolecules with a tailored architecture that 
maximises surface area per unit mass as compared to with other nano-delivery systems. 
End-group functionalisation allows the refinement of their biological and physicochemical 
properties according to the demands of each target use. However, there have been voiced 
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concerns regarding the limited data available on the health and environmental implications 
of the use of dendrimers.20  
 
Lyotropic liquid crystals may be considered as complex molecular structures that possess 
nano-cavities of an aqueous liquid that is separated by lipid bilayers.21,22 
 
To allow for sustained delivery, irrespective of their nature, nanoparticles (Figure 1.1) 
must incorporate the active within the bulk of their structure. Functionalisation with a 
targeting ligand may impart specificity for a cell/organ and may bestow benefits regarding 
issues of toxicity or of side effects.23–26 Integral to the successful commercialisation of 
nanoparticulate dosage forms is the development of efficient and economical methods for 
their large-scale production. 
 
1.2. Preparation of nanoparticles 
 
The methods for producing nanoparticles can generally be classified into two main 
categories: those requiring a polymerisation reaction (such as emulsion and interfacial 
polymerisation) and those produced using macromolecules/preformed polymers (such as 
milling and spray drying).27-28 Some of the main nanoparticle production methods are 
detailed in Table 1.1. Electrohydrodynamic atomisation also uses preformed polymers 
however this method is discussed in more detail in the next section.  
 
There are a number of disadvantages associated with the techniques for producing particles 
presented in Table 1.1: emulsification usually results in particles that have a large size 
distribution,29 and some techniques require extremely high temperatures and high shear 
stresses leading to reduced bio-functionality of the incorporated drugs.30–32 These issues 
are of particular concern when biomacromolecules or other sensitive drugs are used as the 
payload; to eliminate or at least minimise these effects, more steps need to be incorporated 
into the development process, therefore making the fabrication more complicated overall. 
A technique that has the potential to overcome a number of the issues presented is 
electrohydrodynamic atomisation.   
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Table 1.1. Examples of mainstream methods for nanoparticle production.  
Type Technique Comments 
 
 
 
 
Involving 
polymerisation 
reaction 
Interfacial 
polymerisation 
Polymerisation of two monomers separately dissolved in different phases; the reaction takes place at the 
interface of the two liquids33,34; a well-established method for the preparation of polymeric nanoparticles.35–
38  
Single/double 
emulsification 
Simple or multiple emulsions for encapsulation of lipophilic or hydrophilic drugs,39 where both oil in water 
and water in oil emulsion can exist simultaneously. Preparation can be a multi-step process and requires 
different surfactants (both lipophilic and hydrophilic) and stabilising agents.40,41  
Nanoprecipitation 
(solvent displacement) 
Both polymer and active drug are dissolved in a solvent with a low boiling point, the solution being then 
added slowly to a miscible non-solvent until colloidal stability is reached (usually followed by evaporation 
of the volatile phase, though various separation methods can be employed).10,42 
Electrostatic 
complexation 
(ionotropic gelation) 
Relies on attractive forces of counter ions to achieve inter molecular crosslinking of macromolecules; 
examples include chitosan and hyaluronan, dextran sulphate or tripolyphosphate.43–48  
 
 
Preformed 
polymer/ 
macromolecule 
 
Spray drying 
Solutions are converted into solid particles by drying individual droplets (compressed gas converts the 
liquid into a spray); cyclonic separation of particles,49–51 usually in the micrometre range52,53 though 
nanoparticles can also be produced.54  
 
 
Milling 
Nano-sized particles containing poorly water-soluble compounds can be created by advanced milling 
(modified versions of commercially available mills from paint and photographic industries).55 This 
generally leads to a monodispersed product56; main disadvantages of milling for nanoparticle production 
include the low energy efficiency of the grinding process and the need to strictly control the temperature in 
case of labile actives.  
4 
 
Some issues known for the use of nanoparticles in medicine include, the effects of 
additional materials to the nanoparticles and scaling up production for application. Adding 
on targeting agents to the surface of nanoparticles can alter their characteristics, resulting 
in a shortened duration in the blood circulation and less stability – losing two desirable 
characteristics of nanoparticles. The scaling up of nanoparticle production can be a costly 
procedure with re-formulation for application being difficult and time consuming.57,58  
 
With this in mind the advantages of targeted nanoparticles within nanomedicine can still be 
worth the expenditure, Doxil (liposomal form of doxorubicin) allows for a better quality of 
patient life due to reduced toxicity.  
 
1.3. Electrohydrodynamic atomisation 
 
Near the beginning of the twentieth century it was demonstrated by Zeleny59 that fine 
droplets could be formed from a conical shaped meniscus of a liquid under the influence of 
electrical stress (Figure 1.2). Zeleny studied how electrostatic forces affected the behaviour 
of thin liquid jets by using a capillary-plate experimental configuration,60 and further 
research confirmed the potential of electrohydrodynamic atomisation (EHDA) as a 
versatile method for liquid atomisation.61,62 In 1934 Formhals invented several systems 
from which yarns were produced from electrospun fibres, including designs that did not 
even require a spinneret63; many of the recent electrospinning setups can be traced back to 
Formhals, as his work led to many patents being filed. A schematic of a simple 
experimental set up is presented in Figure 1.6. 
 
  
Figure 1.2. Schematic showing the transformation of a liquid meniscus subjected to 
increasing applied voltage into a conical shape and into a jet, which then emerges into 
droplets.64  
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Another breakthrough in this area came in 1964, when the first theoretical description of 
the phenomena affecting the pending droplet at the capillary nozzle exit was published;65 
the conical shape of the liquid, affected by a hydrostatic balance between electrical and 
surface tension forces, is now commonly known as the ‘Taylor cone’.  
 
Over the last decades EHDA was proved to be a versatile technique that could be used for 
the development of a multitude of both micro- and nanometre structures; by tuning the 
process variables, the fabrication of a wide range of constructs (from spherical 
homogeneous particles and capsules to stratified fibres) becomes possible (Figure 1.3).  
 
 
Figure 1.3. Different morphologies produced using EHDA: nanoparticles (A); nanofibres 
(B); hollow nanofibres (C); nanoparticles embedded in fibres (D); and E-jet printing 
pattern (E); from ref. 66–70 
 
 
EHDA has demonstrated many uses in an array of applications including drug delivery, 
due to its ability to be applied in one-step, under normal conditions and with solvents that 
are compatible with the solutions being administered. The versatility of EHDA allows 
particles to be formed with a very small diameter, however the effect of electrical forces 
upon the liquids considered varies considerably with a number of parameters that need to 
be investigated first for each particular application.  
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1.3.1. Spraying modes 
Several spraying modes have been discussed in the literature (starting with the research 
work of Hayati et al.,71,72 Cloupeau and Prunet-Foch,73,74 Shiryaeva and Grigor’ev,75 and 
Jaworek and Krupa76,77); they vary in their formation of the meniscus, pattern of motion of 
the jet, and the method of disintegration, and are controlled by a number of important 
parameters that will be presented later in detail.  
 
There are two main groups of spray type/mode: dripping and jet mode, each with a number 
of sub groups.62 Dripping modes are distinguishable as fragments of liquid dispersed from 
the capillary nozzle outlet, which at some distance contract into spherical droplets. Jet 
modes involve the liquid elongating into a long, fine jet, which only then disintegrates into 
droplets under the influence of the electrostatic forces. Table 1.2 shows the breakdown of 
the main spraying modes (depicted in Figure 1.4).  
 
Table 1.2. A summary of the main EHDA spraying modes.  
Spraying mode types 
Dripping  Jet  
Dripping 
(A) 
Regular large droplets. Cone jet 
(E) 
A smooth and 
stable liquid jet. 
 
Micro-
dripping 
(B) 
Fine droplets with a narrow size 
distribution and low frequency, 
generally occurs at low liquid 
flow rates. 
 
Precession 
(F) 
The liquid jet 
rotates around the 
capillary axis. 
 
Spindle 
(C) 
Occurs at high flow rates along 
with increased electrical forces 
and produces elongated spindles. 
 
Oscillating 
(G) 
Liquid jet 
oscillates in its 
own plane. 
 
Multi- 
spindle 
(D) 
Occurs at higher flow rates 
along with increased electrical 
forces and produces multiple 
elongated spindles. 
 
Multi- 
jet 
(H) 
A few fine jets on 
the circumference 
of the capillary 
exit. 
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Figure 1.4. A schematic representation of the main EHDA spraying modes (adapted from 
ref. 62); letters relate to the explanations given in Table 1.2. 
 
 
When starting an EHDA system, the dripping mode is acquired first; this can then be 
transferred to a more preferred atomisation mode (such as cone-jet) by increasing the 
applied electric field strength.78 The cone-jet mode is normally preferred for nanoparticle 
production as it produces a uniform, stable and continuous jet that leads in turn to more 
controllable particle size.62  
 
The cone-jet mode has been defined by the geometry of the liquid having a conical shape 
ended by a jet73,79,80 (Figure 1.4 E); based on equilibrium considerations of 
electrohydrodynamic atomisation, a number of relationships between the droplet diameter 
and experimental parameters, have been established.81,82 In brief, when an electric field is 
applied, both negative and positive charges separate within the liquid and charges of the 
same polarity as the nozzle move towards the surface of the droplet, inducing a surface 
charge density (liquid flow shown in Figure 1.5). Several factors (parameters) can affect 
the spraying mode, but the applied voltage is acknowledged as most critical in achieving a 
cone-jet mode. 
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Figure 1.5. Main forces applied during electrospraying in cone-jet mode and circulation of 
the liquid within the cone (from 78,83). 
 
 
Previous studies have shown that a stable cone-jet mode can be produced with a solution of 
poly(lactic-co-glycolic acid), or PLGA, as polymeric carrier.84 As demonstrated by the 
work of Kim and Turnball,85 De la Mora and Loscertales,81,86 Gañán-Calvo et al.82 and 
Hartman et al.,87–89 achieving cone-jet mode is dependent on certain properties of the liquid 
involved (which include electrical conductivity, surface tension, viscosity, relative density 
and electric permeability) and on a number of process parameters (such as applied flow 
rate and voltage).90  
 
When low voltage is applied (e.g. ~ 4 kV) the resulting spraying mode can be micro-
dripping, spindle or unstable cone-jet; with very high voltage (e.g. ~ 11 kV) spraying can 
turn to multi-jet. 
 
Viscosity affects the process of the droplet break up, which in turn impacts on the size of 
the droplets produced. To acquire a stable cone-jet the electrical stresses must overcome 
the surface tension, however research has shown that droplet size becomes independent of 
the surface tension when liquids are highly conductive.88  
 
When the liquid density increases, cone-jet mode can still be acquired by decreasing the 
minimum flow rate. If the flow rate used is below a critical value, the cone-jet becomes 
unstable and the droplet size distribution becomes more polydisperse, however above a 
minimum flow rate the generation of droplets stabilise resulting in a narrowing of the 
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droplet size distribution. The minimum flow rate is dependent on surface tension and 
electrical conductivity, as it has been shown in the work of Gañán-Calvo et al.82 and 
Rosell-Llompart et al.91   
 
 
1.3.2. Single needle electrospray 
Single needle electrospray involves the liquid flowing through a single capillary and it has 
been shown to produce monodispersed particles within the nanometre range when using 
the cone-jet mode. As it reaches the capillary nozzle, the meniscus of the liquid forms a 
conical shape due to the electrostatic forces applied. A simplified schematic of the 
equipment used for single needle electrospray is presented in Figure 1.6.  
 
 
 
Figure 1.6. Schematic representation of a single needle electrospraying system. 
 
A diagram depicting the process of particle formation via EHDA can be seen in Figure 1.7. 
During the evaporation of a fine droplet, the powder suspended in it will form a tight 
cluster. Electrospraying is a versatile tool for both micro- and nanoparticle production62 as 
it can produce extremely small, monodispersed particles. The droplets produced have an 
electric charge, allowing them to self-disperse due to mutual repulsion that prevents the 
droplets from coagulating. The deposition efficiency of a charged spray on a given surface 
	   
Syringe 
pump 
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High DC  
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Sample 
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is order of magnitudes higher than for uncharged droplets. A therapeutic agent can 
sometimes be easily incorporated into the polymer solution, where during the drying 
process it will then be uniformly dispersed within the polymeric matrix without any 
aggregation due to the residual changes.92  
 
 
 
Figure 1.7. Process of particle formation during electrospraying (adapted from 62). 
 
The process is however more complicated. In the cone-jet mode, the liquid flowing 
downstream and the droplets that break up are affected by instability, which can be of two 
types: kink and varicose. The ‘kink’ instability was explained by a number of additional 
factors such as aerodynamic tangential drag force,93 lateral growing factor94 and 
electrostatic pressure,74 while the ‘varicose’ instability is still being investigated by many 
researchers interested in how it affects the break-up of the jet in the electric field.95–98 
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Research by Pancholi et al.99 has shown that EHDA can produce spherical chitosan 
particles when using the stable cone-jet mode; the particles were uniform and of a size less 
than 10 ?????????????????????????ter and size distribution of the particles were both found 
to be related to the viscosity of the solutions employed; changing the nature of solvents 
and/or the properties of solutions employed allows for controlling the structure and 
morphology of the particles.100    
 
1.3.3. Co-axial needle electrospray  
 This type of system consists of two concentric needles supplying simultaneously two 
liquid jets, as can be seen in Figure 1.8. This provides a one-step easy method of 
encapsulating a drug within a polymeric carrier; the drug and coating material are initially 
kept separate prior to feeding through the two co-axially aligned capillaries, when particles 
with core (drug) – shell (polymer) structure can easily be formed. This has been 
demonstrated by Lee YH et al.101 with drug-loaded monodispersed PLGA particles of 
different sizes, produced with high encapsulation efficiency (90 – 95 %). 
 
An inviting aspect of a co-axial electrospray system is that it can produce particles that 
have a narrow size distribution with a mean diameter varying from micro- to nanometres, 
normally by varying the main process parameters (such as flow rate, needle diameter and 
applied voltage).102–105 
 
 
Figure 1.8. Simplified representation of a typical co-axial needle set-up for 
electrospraying (high voltage supply, as in figure 1.6, has not been included). 
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Research has already shown that co-axial jets are a viable technique for encapsulating 
materials with the potential for use in drug delivery applications106 and for the generation 
of ceramic-ceramic composite microstructures.107 Nangrejo et al. produced data showing 
that alumina and zirconia layered encapsulation is possible using a co-axial electrospray, 
however high flow rates were required for concentrated suspensions (10 to 20 % volume) 
to ensure prolonged flow and jetting.107  
 
 
1.3.4. Multi-axial electrospraying  
Electrospray systems using three (or even four) co-axial needles have been used to produce 
various particle morphologies that could offer many potential benefits for applications in 
tissue engineering, fibre or thread encapsulation and drug delivery (carrier vesicles and 
also multi-layered micro- and nanocapsules). 
 
 
Figure 1.9. Simplified diagram of a tri-axial needle set up.  
 
 
Ahmad et al.103 have shown that by adding the third needle multiple layered bubbles of air, 
glycerol and olive oil could be prepared (Figure 1.9). This allows for the prospect of 
multiple loading, as well as the ability for variation of the surface properties of the multi-
layered bubbles (meaning they could be either hydrophilic or hydrophobic). Another 
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advantage is that an enhancement of the properties of the bubbles can occur for ultrasonic 
applications from a modification of the surface of the bubbles.108  
 
The spatial arrangement of the needles was found to have a massive impact on the 
efficiency of the process. Also, only under specific conditions (applied voltage 6.5 – 8.0 
kV and ??????????????????????????????? min-1 for air, glycerol and olive oil respectively), 
the concentric encapsulation of air going through the inner needle was successful as 
demonstrated by the SEM investigations of the layered particles.103 
 
 
1.3.5. Other EHDA techniques 
1.3.5.1. Electrospinning 
It has been shown previously that thin continuous fibres can also be produced from a liquid 
subjected to an electric field58; the appeal of this technique is the versatility it provides, 
allowing the production of nanofibres and nanotubes from virtually any soluble polymer 
(Figure 1.3). These fibres can reach several meters in length while still maintaining their 
diameter within the nanometre range.109 The process works similar to electrospraying; the 
electric field stretches the meniscus forming a conical shape, then a strand of this solution 
is quickly formed. This occurs when a medium with reasonably high viscosity (which can 
overcome any jet instabilities) is used; in this case break-up of the jet does not occur, 
resulting in electrospinning.62,110,111 The solvent will proceed to evaporate as soon as it has 
left the needle.112 The fibre produced does not form in a simple straight line as the 
instabilities of the electrostatic forces cause the material to whip around; this results in 
thinning of the fibres and enhanced solvent evaporation leading to the final product as a 
collection of solid nanofibres.  
 
The fibres that can be produced (by either mono-, co-axial, or multiple needle 
electrospinning techniques) allow for extensive uses in drug delivery applications due to 
their versatility; the fibres can be either hydrophilic or hydrophobic and have a size range 
from ????????????????????????????????????????????????????????????????????????????????-
axially can have antibiotics, proteins and drugs incorporated into them for a sustained 
release effect,113–117 though the release and distribution of actives from these fibres were 
poorly controlled.115,118 There are still limitations with a single needle electrospinning 
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system, as not any polymer solution can be electrospun (for instance solutions with high 
surface tension or low electrical conductivity).119 In these cases, co-axial electrospinning 
can overcome the problem, with the polymer solution being fed through the inner capillary 
while another solution suitable for electrospinning flowing through the outer capillary. 
 
1.3.5.2. E-jet printing  
E-jet printing is a manufacturing process employed as a printing technique in both micro- 
and nano-scale ranges.11,111  E-jet printing uses an electric field to fluid jet print through 
micro/nano-scale nozzles. This type of printing process is primarily controlled by changing 
the voltage potential between the nozzle and the substrate.123 This technique differs from 
the conventional ink-jet printing processes that use either heat or pressure to force the fluid 
flowing. The process used for E-jet printing is the same as that of electrospraying, however 
the droplets are collected considerably closer to the capillary nozzle. The droplets can be 
guided, as they are ejected from the capillary, to form a specific design, as desired. 
Research has suggested that the most efficient spraying modes for E-jet printing are 
pulsating and cone-jet, as they can ensure controllable printing.124,125  
 
E-jet printing is more advantageous compared to ink-jet printing due to using significantly 
larger capillary nozzles that minimise needle blockages, resulting in easier processing of 
viscous polymer solutions. This technique also allows finer scaffold dimensions to be 
produced,11 as micro-sized fine nozzles can be used along with control over the jetting time 
and a low flow rate to allow for the delivery of very small volumes.122,126 The appeal of 
using E-jet printing for micro and nano-sized patterns is that droplets that are significantly 
smaller than the diameter of the nozzle can be ejected; also, versatile materials can be used 
without thermal damage occurring, and the structure of the nozzle is simpler than in other 
cases.127 
 
Wang et al. has shown that it is possible to have a fully voltage-controlled E-jet printing 
system for organic silver ink, when either steady or transient jetting is used. Using 
unforced E-jet printing, in cone-jet or pulsation mode, has been proven to allow specific 
pattern deposition in a controllable manner.11 
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1.3.6. Main process variables 
Amongst the many parameters that can affect the EHDA process,12 the most critical ones 
are summarised in Figure 1.11: system parameters (flow rate, applied voltage, collection 
distance, as the ‘working distance’ between the needle outlet and the collecting plane) and 
the properties of the liquid being electrosprayed (viscosity, surface tension, electrical 
conductivity, density and dielectric constant). They are all discussed further in Chapter 3.   
 
 
 
Figure 1.11. The main processing parameters for electrospraying. 
 
 
1.4. Polymeric materials historically employed in EHDA studies 
 
Various polymers have been researched for effective drug delivery to a target site as 
polymeric nanoparticles have been shown to be advantageous over liposomes for drug 
delivery purposes due to their ability to increase the stability of drugs and proteins and to 
control the release.12 Many polymers are also generally biodegradable (with breakdown 
products not toxic to the body) and offer outstanding biocompatibility.  
 
 
EHDA Parameters 
Physical properties 
of liquid 
System Parameters 
Surface 
tension 
Viscosity 
Electrical 
conductivity 
Flow rate 
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voltage 
Collection 
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Density 
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1.4.1. Poly(lactic acid) 
Poly(lactic acid), or PLA (Figure 1.12), is known for its biocompatibility and 
biodegradability characteristics; under physiological conditions it gradually breaks down 
into simple, stable and non-toxic end-products,130 being therefore an ideal candidate for 
biomedical applications. Degradation normally occurs by autocatalytic hydrolytic cleavage 
of the ester bonds to lactic acid, which then fully degrades into carbon dioxide and water, 
though the effect of anaerobic or aerobic microorganisms or other biological reactions 
have also been considered as possible causes for initiating the degradation.131,132 
 
At body temperature, PLA-based polymers in particulate form decompose within days, 
with the process being obviously size dependent; structures larger than 10 µm take longer 
to decompose as they are too large to undergo phagocytosis.133,134    
  
O
O
n
 
Figure 1.12. Structure of poly(lactic acid), PLA. 
 
PLA is produced by polymerisation of lactic acid (Appendix A); the catalytic ring-opening 
of the lactide intermediate produces PLA with controlled molecular weight and physical 
properties.135–137 
 
1.4.2. Poly(lactic-co-glycolic acid)  
Poly(lactic-co-glycolic acid), or PLGA (Figure 1.13), is a biocompatible copolymer that 
can easily degrade by breaking down into its building block monomers namely lactic and 
glycolic acids, which are both endogenous and are being metabolised straightforwardly in 
the body via the Krebs cycle.  
 
The copolymer properties - including degradation time, a critical characteristic for 
biomedical applications - can be conveniently tuned by varying the ratio of the two 
monomers.138,139 As it has limited systemic toxicity, PLGA is an extremely popular 
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material for biomedical applications and was approved by the European Medicine Agency 
(EMA) and by the US FDA.140  
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Figure 1.13. Structure of poly(lactic-co-glycolic acid) (A) and its by-products lactic acid 
(B) and glycolic acid (C).  
 
Previous investigations of PLGA for nanoparticulate drug delivery applications have 
shown that PLGA inherently has low drug loading (around 1 %), however encapsulation 
efficiencies are generally high.3 Also, nanoparticles produced from PLGA-based materials 
showed an initial burst release, typical for systems where an important percentage of the 
loaded drug is present on the surface of the nanoparticles.140 Diffusion through the matrix 
of the polymer combined with matrix erosion due to degradation are commonly accepted 
mechanisms for drug release in PLGA based materials.  
 
In this work, the symbols used for copolymers include the co-monomer ratio (as % molar 
composition); for instance, PLGA 50:50 is made up of 50 % lactic acid and 50 % glycolic 
acid.  
 
1.4.3. Applications of PLA/PLGA nanocarriers 
A brief summary of applications considered so far for PLA and PLGA based nanoparticles 
is presented in Table 1.3. A majority of applications focus on cancer treatments, with 
several in vitro studies generating very promising results. 
 
A 
C 
B 
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Table 1.3. Examples of studies employing PLGA and PLA nanocarriers for drug delivery applications.  
Materials Active/ 
Drug 
Technique Details 
PLGA Naficillin Single 
emulsion/solvent 
evaporation 
Nafcillin loaded PLGA nanoparticles for the delivery of antibiotics to osteoblasts for the 
successful treatment of Staphylococcus aureus-mediated osteomyelitis.141 
PLGA  (with PVA 
and PLL*) 
Curcumin Nanoprecipitation Curcumin encapsulated within PLGA, PVA and PLL with improved anti-cancer potential in 
cell proliferation compared to the free active.142 
PLGA, PLA  Doxorubicin 
(DOX) 
Nanoprecipitation DOX loaded PLGA nanoparticles stabilised with bovine serum albumin were found to 
effectively deliver large amounts of DOX in active form to breast cancer cells.143 Both 
PLGA and PLA nanoparticles shown to release DOX too quickly to overcome MDR.144 
HA-PEG-PLGA* Doxorubicin Nanoprecipitation HA-PEG-PLGA nanoparticles (~150 nm) reduced tumour volumes in mice significantly 
more than MPEG-PLGA nanoparticles.145 
PEGylated PLGA Doxorubicin Single emulsion Avidin-biotin coupling used for PEG conjugation to PLGA nanoparticles (~130 nm) with 
encapsulated DOX being as potent as free DOX (A20 murine B-cell lymphoma). 
Pathological changes (creatine kinase level increase and ventricular fractional shortening) 
induced by free DOX not observed with loaded nanoparticles.146 
PLGA + poloxamer 
188 
Docetaxel Oil-in-water 
emulsion/solvent 
evaporation 
PLGA + poloxamer nanoparticles (~200 nm) had a significant cytotoxic increase on breast 
cancer cells compared to PLGA nanoparticles.147 
PLA-PCL*, 
PLGA-PCL 
Docetaxel Nanoprecipitation Nanoparticles (100-200 nm) increased cytotoxic effects on PC3 cells compared to the free 
active.148 
PLGA, 
PLGA/MMT*, 
PLA-TPGS*, PLA-
TPGS/MMT* 
Docetaxel Polymerisation 
reaction 
Docetaxel loaded nanoparticles tested in vitro with significantly higher cytotoxic effect 
compared to the current Docetaxel clinical formulation.149 
 
*	  PVA; poly(vinyl alcohol), PLL; poly-L-lysine, HA; hyaluronic acid, PEG; polyethylene glycol, PCL; polycaprolactone, vitamin E TPGS; d-?-
tocopheryl polyethylene glycol 1000 succinate, MMT; montmorillonite,
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2. Aim and objectives 
 
 
The work described in this thesis was aimed at exploring the capability of 
electrohydrodynamic atomisation (EHDA) as an effective technique for the fabrication of 
tumour targeted nanoparticles based on PLA and PLGA that can be loaded with 
chemotherapeutics and further employed for anticancer drug delivery applications. The 
following objectives were considered: 
? Investigate and optimise the EHDA main process parameters for the single-needle 
fabrication of a range of PLA and PLGA nanoparticles;  
? Employ single-needle EHDA techniques to incorporate fluorescent drug surrogates, 
model drugs and specific cancer targeting moieties into nanoparticles using a single 
step procedure;  
? Optimise the EHDA protocols for the fabrication of loaded nanoparticles on a scale 
suitable for in vitro investigations; 
? Comparatively assess cytotoxicity and cellular uptake of loaded nanoparticles in 
vitro using both cancerous and normal human cells; 
? Investigate the role of targeting moieties such as folic acid in ensuring selective 
drug delivery to cancerous cells. 	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3. Preparation of PLA/PLGA nanoparticles using EHDA: 
parameter optimisation  
 
 
3.1. Introduction 
This chapter presents the results of an optimisation study of the EHDA process parameters 
with the aim to produce PLA and PLGA nanoparticles with minimal size; collection 
distance (CD), applied voltage, flow rate and polymer/drug concentration were the main 
variables investigated for their effect on particle diameter.  
 
3.1.1. EHDA parameters  
There are several variables that affect the results obtained when working with the EHDA 
technique and most of them are interdependent; the main parameters are presented in Table 
3.1 and their effect is discussed further below. In combination, these variables determine 
the size, shape, morphology and drug loading of the particles produced by EHDA.  
 
Table 3.1. Main parameters affecting EHDA.  
 
Parameter 
type 
Parameter [units] Main effects on EHDA References 
 
Operational 
Flow rate [µL/min] Size and drug loading 1–3 
Applied voltage [kV] Size and shape 2,4 
Collection distance [cm] Size - 
 
 
Solution 
properties 
Viscosity [mPa s] Size and shape 5,6 
Surface tension [N m-1] Ability to be eligible 
for EHDA 
7,8 
Electrical conductivity [S m-1] Size 2 
Density [kg m-3] Droplet diameter 9 
Dielectric constant [-] Ability to be eligible 
for EHDA 
10 
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Table 3.2. Relevant equations proposed in the literature; the main variables affecting the electrospraying technique. 
Equation 
number 
 
Equation 
 
Variables 
 
Comments 
 
3.1 ?? =	   ??????????  ??????????????????????????-3)    ?0 = solution dielectric constant (-) ???????????????????????????????? -1) 
K = solution conductivity (S m-1) 
? = solution viscosity (cP) 
Provides a dimensionless number (?m) that can 
estimate the effect of viscosity on the process of 
droplet formation; proposed by Gañán-Calvo et al.11 
 
3.2  
d = droplet diameter (m) 
????constant (dependent on liquid permittivity) 
Q = liquid flow rate (m3 s-1)  
?r = relative permittivity of vacuum (-) 
?1 = electrical conductivity (S m-1)  
For the estimation of the droplet size when 
electrospraying in cone-jet mode; proposed by De La 
Mora et al.12 
 
 
3.3  
?1 = density (kg m-3)    
?1 = surface tension (N m-1)   
Equation proposed by Hartman et al.13 for the 
estimation of droplet diameter when electrospraying in 
cone-jet mode.   
 
3.4  
As above.  Equation proposed by Gañán-Calvo14 for the 
estimation of the size of the droplet produced during 
electrospraying.  
 
3.5  
ƒ = mass fraction of material in solution (-) 
?droplet = density of solution (kg m-3) 
?particle = density of produced particle (kg m-3)  
Estimates the diameter of the particles produced (dp), 
in dried state, using the droplet size.15 
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The surface tension of solutions subjected to electrospraying is one of the important 
limiting variables, and it has been reported in the literature that the surface tension needs to 
be lower than 50 mN/m for a liquid to be atomised under the influence of electrical 
forces.15 The flow rate of the solution pumped through the needle can also have a 
substantial effect on the particle diameter: an increase in flow rate was generally found to 
lead to larger particles.4,16 
 
The viscosity of the solution being electrosprayed has a significant effect on the 
morphology of the particles produced; as viscosity increases particles will start elongating 
into fibres so the process can gradually go from electrospraying into electrospinning. As a 
result, solutions that are above a certain viscosity are simply not appropriate for 
nanoparticle production.17 Equation 3.1 (Table 3.2) was introduced by Gañán-Calvo11 to 
provide a dimensionless number (?m) that can estimate the effect of viscosity on the droplet 
formation process. If the ?m value is greater or equal to 1, the effect of the viscosity on 
droplet size was found to be insignificant, while a value lower than 1 indicates that the 
droplet size would increase significantly with increasing viscosity.   
 
Many equations that attempt to determine the size of the droplet produced from 
electrospraying in cone-jet mode have been proposed, and several more examples are 
presented in Table 3.2. However, the equation for estimated droplet size that has been 
confirmed by most experimental results is Gañán-Calvo’s (Equation 3.4), which was 
determined theoretically from the scaling laws, and which is also used in this work. From 
all equations presented in Table 3.2 (Equations 3.2 – 3.4) it can be seen that the droplet 
diameter increases with the flow rate and is inversely proportional to the liquid 
conductivity.  
 
The diameter of the particles produced in dried state by electrospraying (dp) can be 
estimated using Equation 3.5 (where the size of the droplet must be known/calculated 
first). This equation has been validated for platinum nanoparticles and is potentially 
applicable for many types of materials produced by electrospraying, however it has been 
suggested that it is not suitable for particles that are porous or hollow.18,19  
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3.1.2. PLA/PLGA electrosprayed nanoparticles  
Due to their biocompatibility and biodegradability, PLA and PLGA are amongst the most 
studied polymers for drug delivery applications. Nanoparticle preparation methods include 
electrospraying, and the versatility of this technique as a one-step method to incorporate 
drugs within nanoparticles without affecting their structure is clearly demonstrated by the 
variety of applications considered. However, most of the existing literature focuses on 
PLA/PLGA microparticles produced by single needle electrospraying,20,21 while reports of 
particle fabrication in the nanometre range are still very limited; a summary is presented in 
Table 3.3.  
 
Table 3.3. Literature reports of PLA/PLGA nanoparticles prepared by electrospray. 
Particle 
Composition 
Application Details References 
PLGA 
50:50 
Model for paclitaxel 
delivery (no release or in 
vitro studies). 
Particles with a diameter of 
250 nm were produced. 
 
1 
 
PLA 
Mw = 2000 g 
mol-1 
Prove both hydrophilic and 
hydrophobic drugs can be 
incorporated in particles 
using EHDA. 
PLA nanoparticles (average 
diameter of 200 nm) loaded 
with beclomethasone-
dipropionate or salbutamol-
sulfate. 
 
 
22 
 
PLGA 
 
Bone stimulation (in vitro). 
Titanium implant with 
electrosprayed PLGA and 
bFGF nanoparticles (average 
260 nm) for bone stimulation.  
 
23 
 
PEG- 
PLGA 
Drug carriers for effective 
targeted delivery of 
chemotherapeutic agent for 
CD44-positive ovarian 
cancer. 
 
Cisplatin encapsulated CD44-
PEG-PLGA nanoparticles 
(average size 550 nm).  
 
 
24 
* bFGF, basic fibroblast growth factor. 
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The	  data	  in	  Table	  3.3	  looks	  at	  nanoparticles	  around	  250	  nm,	  however	  nanoparticles	  of	  a	  smaller	  size	  (around	  50	  nm)	  are	  known	  to	  have	  a	  higher	  cellular	  uptake	  (some	  cell	   lines	  could	  vary).25,26	  One	  reason	   for	   this	   is	   that	   larger	  nanoparticles	   (above	  50	  nm)	  have	  more	  ligand-­‐to-­‐receptor	  interactions	  per	  particle,	  thereby	  allowing	  them	  to	  bind	  to	  a	  greater	  number	  of	  receptors	  resulting	  in	  additional	  nanoparticles	  not	  being	  able	  to	  bind.	  The	  uptake	  becomes	  limited	  by	  the	  redistribution	  of	  receptors	  on	  the	  cell	  membrane	   via	   diffusion.	   Optimal	   cellular	   uptake	   and	   endocytosis	   has	   been	  mathematically	  predicted	  to	  occur	  when	  there	  are	  no	  localised	  receptors	  available	  on	  the	   surface	   of	   the	   cell	   and	   there	   is	   no	   shortage	   of	   ligands	   available	   on	   the	  nanoparticle.27 
 
3.1.3. Nanoparticle characterisation methods  
Size, morphology, zeta potential and drug loading capacity are important characteristics 
defining a nanoparticulate drug carrier system. The size of nanoparticles can be measured 
using dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA). 
Nanoparticles can be visualised for shape and size using scanning electron microscopy 
(SEM), transmission electron microscopy (TEM) as well as atomic force microscopy 
(AFM). The zeta potential (measured using electrophoretic mobility, EPM; i.e. 
investigating the behaviour of the nanoparticles under an electric current) of a colloidal 
system provides a good indication of the stability of those nanoparticles in a specific 
media. Drug loading can be visualised under confocal/fluorescent microscope (when 
fluorescent actives are being used) and quantified using high performance liquid 
chromatography (HPLC) with a fluorescence detector or ultraviolet light spectroscopy 
(UV). Specific details about each technique employed in the work described in this chapter 
are presented below.  
     
3.1.3.1. Nanoparticle tracking analysis  
NTA is a relatively new sizing method for measuring particle diameter by tracking their 
Brownian motion in specific media; the typical range is between 30 to 1000 nm, with the 
refractive index of the nanoparticles determining the lower detection limit.28 NTA was 
commercialised by Carr et al. under the NanoSight brand,29 and beside size it can measure 
size distribution, concentration, zeta potential and fluorescence intensity, on a particle-by-
particle basis. The method allows real time visualisation of the nano-structures, in liquids, 
	  	   43	  
employing a laser to track and capture the Brownian movement of the particles with a 
camera (30 frames/sec) mounted onto a microscope (schematic in Figure 3.1).30 To 
calculate the hydrodynamic diameters of the particles, the software then uses the Stokes-
Einstein Equation (Equation 3.6). 
 
? =	   ???????  
 
D = diffusion coefficient (m2/s)   ????????????????????? (Pa/s) 
kB = Boltzmann constant (J/K)  r = radius of spherical particle (m) 
T = absolute temperature (K). 
 
 
Figure 3.1. Diagram representing the principle of NTA (adapted from 31). 
 
NTA measures the diameters of particles on an individual basis, which is more 
advantageous compared to DLS (which measures the intensity average distribution) when 
measuring polydisperse samples.30 Figure 3.2 shows typical tracks of individual particles 
moving under Brownian motion.  
Equation 3.6. 
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Figure 3.2. Diagram indicating typical tracks from particles moving under Brownian 
motion.32  
 
 
3.1.3.2. Dynamic light scattering 
DLS (known also as Photon Correlation Spectroscopy, PCS, or Quasi-Elastic Light 
Scattering, QELS) is one of the well-established and widely used methods for particle 
sizing as it is user-friendly, fast, and yields consistently accurate results.33  
The particles dispersed in a liquid media are illuminated by a laser beam and the changes 
detected in the intensity of the scattered light (which can be measured at different angles) 
are converted into particle size using the same Stokes-Einstein equation (Equation 3.6, as 
described in section 3.1.3.1).34 The particle’s Brownian motion causes the laser to be 
scattered at different intensities, and the intensity fluctuations yield the velocity of the 
Brownian motion (Figure 3.3). The DLS technique is most suitable for monodispersed and 
non-fluorescent samples. DLS delivers better statistics than SEM as it requires a larger 
sample size, however a limitation of DLS is the bias towards larger particles due to them 
scattering more light.35 
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Figure 3.3. Schematics detailing DLS with a 90 º scattering angle (top) and the scattering 
volume and subsequent static and DLS intensities (bottom).36  
 
 
3.1.3.3. Zeta potential - EPM 
Zeta potential is a measure of the charge attraction or repulsion that occurs between 
particles in a solution and it is one of the key characteristics estimating the stability of a 
colloidal system.37 The zeta potential is determined at the slipping plane (Figure 3.4) by 
measuring the electrophoretic mobility (EPM) of particles in solution by light scattering, 
and then converting it to zeta potential.38 A solution of particles is introduced into a 
specialised cell that contains two electrodes (Figure 3.5) and an electrical field is applied 	  	   46	  
resulting in the particles with a net charge migrating towards the oppositely charged 
electrode, with a velocity that can be related to their zeta potential.38 
 
 
 
Figure 3.4. Schematic representation of a charged particle; the zeta-potential is measured 
at the slipping plane (adapted from 39). 
 
 
 
 
 
Figure 3.5. Specialised cell for zeta potential measurements demonstrating the movement 
of particles under an electric field (Malvern, proprietary; adapted from 40). 
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3.1.3.4. Atomic force microscopy 
AFM is a technique that usually employs a silicon nitride probe attached to a cantilever to 
scan the surface of a sample (a laser beam magnifies the changes in the position of the 
cantilever,41 Figure 3.6) and thus investigates the surface topography or associated 
phenomena such as friction or magnetism. 
 
 
Figure 3.6. AFM set up and close up image of the cantilever (adapted from 42 and 43).  
 
There are different modes that can be used in AFM: contact and tapping mode. Contact 
mode is the basic mode to obtain height and morphology information, using the deflection 
of the cantilever as the tip scans the surface of the sample. A limitation of this mode is 
obvious when loosely attached nanoparticles are dragged along the surface by the probe or 
where the particles are soft and the probe makes an indent in them.44 Tapping mode is 
meant to overcome this as it works by tapping the cantilever and probe across the sample, 
ensuring the cantilever oscillates close to the resonance frequency required. This in turn 
reduces the applied force on the sample, meaning that soft samples do not endure 
irreparable damage that would have been caused by contact mode.45  
 
 
Sample 
Quadrant 
photodiode Laser 
Cantilever 
Piezo 
scanner 
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3.1.3.5. Scanning electron microscopy 
Nanoparticles cannot be seen under a normal optical microscope, but they can be easily 
visualised using SEM, which typically have a resolution of 10 nm. They are built around 
the electromagnetic lens developed by Hans Busch in 1926, when he was studying 
trajectories of charged particles in electric and magnetic fields.46 A SEM instrument uses a 
fine probe of electrons (with energies between 1 – 50 kV) emitted from a small tungsten 
tip to focus onto the sample.47 A series of lenses are used to help achieve the 
demagnification (known as condenser lenses); the objective lens provides the final step in 
demagnification and focuses the beam of electrons onto the surface (Figure 3.7).  
 
Figure 3.7. Schematic set up of a typical SEM instrument (adapted from 48).  
 
 
Preparing a sample for SEM involves placing it onto a stub that is then coated with gold to 
provide a sufficient conductive layer, which needs to be as thin as possible and must not 
interfere with the sample; this thin layer must have a high secondary electron emission 
coefficient to ensure a good image contrast.49 
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3.2. Experimental details 
3.2.1. Materials 
PLGA (50:50) was purchased from PURAC Biomaterials (Amsterdam, The Netherlands); 
PLGA (75:25) and PLA (both MW 17,000 g mol-1) were kindly provided as a gift by the 
same company. All solvents were of HPLC grade and were purchased from Fisher 
Scientific (Loughborough, UK), unless specified differently. Dimethylacetamide (DMAC), 
Rhodamine B and fluorescein isothiocyanate (FITC) were sourced from Sigma Aldrich 
(Dorset, UK).  
 
3.2.2. Preparation and characterisation of polymer solutions 
Each polymer was dissolved in the specified solvent (acetone, acetonitrile, chloroform, 
dichloromethane, dimethylacetamide, dimethylformamide, dimethylsulfoxide, ethyl acetate 
and tetrahydrofuran) at the required concentration (5 % w/v), and the solution was then 
mechanically stirred for 30 min at room temperature. For solutions containing fluorescent 
drug surrogates (RB and FITC), they were added at this stage (5mg/mL) and stirred for a 
further 30 minutes. All the characterisation measurements described below were run in 
triplicate.  
  
Surface tension (mN/m) 
The surface tension of each solution was measured using the Wilhelmy plate method on a 
?????????????????????????? (Bristol, UK). The solution was loaded onto the platform in a 
glass bowl and the metal detector plate was attached and lowered to near the surface of the 
solution. Before the weight was tared, the machine detects the surface of the solution and 
the metal plate was immersed within the solution; once the metal plate was back to 
touching the surface of the solution the readings were taken. The metal detector plate was 
cleaned with a Bunsen burner between samples.  
 
Electrical conductivity (mS m-1) 
A HANNA electrical conductivity meter (Camlab Ltd, Cambridge, UK), probe was dipped 
into the solution and left for one minute to equilibrate; enough solution was needed to 
completely flush the probe filaments with solution for an accurate measurement.  
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Density (g/mL) 
A 25 mL pycnometer was used for measuring density. The empty bottle was weighed and 
then filled with the solution to be measured, the stopper was put in and the solution should 
project out at the top to ensure that the bottle is full (there should be no air bubbles). Once 
the outside of the bottle was cleaned the bottle was re-weighed. The weight difference 
(weight of the solution) was divided by the pycnometer volume (25 mL) to calculate the 
solution density. 
 
Viscosity (mPa·s) 
The viscosity of the solvents was measured using a U-tube viscometer (size A) at room 
temperature (21 – 22 °C). 10 mL of solution was added to the left side of the viscometer 
and then pulled up on the right side past the top line above the bulb. The time was then 
measured for the solution to go between the two lines (on either side of the bulb) and the 
viscosity was measured using Equation 3.7: 
    ?? = ?? ????????	     Equation 3.7. 
 
????????????????????????????????? ?????????????????3)  t = time (s) 
1 = sample    2 = water 
 
The polymer solutions were measured using an AR2000 rheometer (TA Instruments, 
Elstree, UK) with an aluminium 60 mm cone geometry. Firstly the solutions were tested to 
see if they were non-Newtonian or Newtonian by changing the velocity on a log scale 
(0.02, 0.20, 2.00 and 20.00 m/s). If the viscosity readings were similar for each velocity 
this suggests the sample is Newtonian and therefore a continuous ramp test can be 
undertaken. All the solutions measured (5 % w/v polymer in DMSO with and without 
fluorescent drug surrogates) were Newtonian.   
  
3.2.3. Equation data 
Characterisation data obtained as described above were converted into the units required 
by Equation 3.4 and summarised in Tables 3.3, 3.4 and 3.5. The dielectric constant values 
for the solvents were taken from Smallwood et al.50  
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3.2.4. Electrospray experiments  
Figure 3.8 presents the set up used for the electrospraying experiments. The polymer 
solution at 5 % w/v (prepared as described in section 3.2.2) was loaded into the syringe 
and was fed (at a predetermined flow of 5 µL/min, using an electronic syringe pump 
(Harvard Pump Elite-11, Edenbridge, UK)) through the stainless steel capillary needle 
??????? ????????? ???? ??? connected to a high voltage power supply (Glassman High 
Voltage Inc., Series FC, Glassman Europe, Bramley, UK). The applied voltage varied 
between 7.0 – 8.2 kV to allow for a stable cone-jet to be obtained. Electrosprayed 
nanoparticles were collected in a glass Petri dish placed on the collector containing 15 mL 
ultrapure water, which was then batch freeze-dried (per 1 hour of collection) and stored in 
a desiccator (silica gel) prior to further use.  
 
 
Figure 3.8. The main components of the standard set up used for single needle 
electrospray experiments.  
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3.2.5. Characterisation of nanoparticles 
Scanning electron microscopy 
SEM investigations were carried out using a Jeol JSM-6060LV instrument with the images 
being taken using a Zeiss 710 LSM camera. The samples were mounted on a copper stud 
by placing them onto a sticky carbon tab that was then dried in a N2 stream, then coated 
with a thin layer of Au/Pd in an argon atmosphere for 5 min (Polaron E5000 SEM coating-
units, Quorum Technologies Ltd, East Grinstead, UK). 
 
Nanoparticle size characterisation 
Particle diameter was measured by DLS using a Malvern ZetaSizer Nano-ZS instrument 
(Worcestershire, UK) with Zetasizer software v. 6.01. For measurement, each sample was 
redispersed in deionised water by vortexing for 1 min followed by sonication (5 min) in an 
ultrasonic bath; readings ????? ?????? ??????? ???? ?????? ??????????? ???????? ????? ??? PTFE 
syringe filter (Acrodisc, Life Sciences). Samples were analysed in triplicate, at 25 °C, in 
clear disposable polycarbonate cuvettes following a 2 min equilibration period. Zeta 
potential was determined on the same Malvern ZetaSizer Nano-ZS instrument as above 
following EPM measurements in Malvern proprietary clear folded capillary cells, under 
the same conditions. Size and size distribution measurements were also performed using a 
NanoSight LM 14 Nanoparticle Tracking Analysis instrument (Salisbury, UK) equipped 
with a 532 nm laser and controlled by NTA Tracking Suite 2.2 software.   
 
3.2.6. Release studies 
Freeze-dried nanoparticles loaded with Rhodamine B, as a fluorescent drug surrogate, were 
re-suspended in phosphate buffered saline (PBS) (1.0 mg/mL) by sonication and vortexing 
(1 min each) then kept in a shaking water bath (37 °C). At predetermined time points, 
samples were removed from the water bath and centrifuged (5,000 rpm; 7,982 g; 5 
minutes). The supernatant was removed and the fluorescence was measured (excitation 
480 nm, emission 590 nm, Optima Fluorimeter).  
 
3.2.7. Statistical analysis 
Statistical analysis was carried out using IBM SPSS statistics 22 software. Data sets were 
initially checked for normal distribution (using normality plots); one-way analysis of 
variance (ANOVA) followed by post hoc Tukey test (p values set at 0.05) were used to 
evaluate statistical significance. 	  	   53	  
3.3. Results and discussion 
The preparation of PLA and PLGA nanoparticles by electrospraying was investigated 
using different solvents, and optimisation of the main process parameters (with focus on 
the collection distance) was carried out. Rhodamine B and fluorescein (structures in Figure 
3.9) were employed as fluorescent drug surrogates in an attempt to assess the drug loading 
effect on the electrospraying process.  
 
All starting materials and polymeric solutions were characterised first to assess their 
suitability for the EHDA process. The characteristics measured were used to predict the 
size of the electrosprayed droplets and dry particles and the results were then compared to 
the diameter of the actual particles obtained. 
   
3.3.1. Characterisation of solvents and polymers  
All solvents and polymer solutions were characterised in order to assess their suitability for 
single needle electrospraying and the results are presented in Table 3.4; the dielectric 
constant values were sourced from the literature,50,51 with PLA being used as a reference 
for all polymers.    
 
According to equation 3.4, the diameter of the droplet is expected to be inversely 
proportional to the conductivity of the liquid and proportional to the liquid flow rate. 
Considering the results summarised in Table 3.4, ACN and DMF would therefore appear 
as good solvents for minimising the particle diameter. However, when electrospraying, the 
pure solvents that sprayed easily and with a stable cone-jet were ACN, DCM, and DMSO 
(most stable cone jet).   
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Table 3.4. Characteristics of the solvents used in the electrospraying experiments (n = 6; ? 
SD).  
 
Solvent 
Surface 
Tension 
(N m-1) 
Electrical 
Conductivity 
(S m-1) 
Density 
(kg m-3) 
Dielectric 
constant? 
 
Viscosity 
(mPa s) 
Acetone 23.7 
? 0.0 
0.528 
? 0.008 
741.0 
? 0.0 
21.0 0.334 
? 0.036 
ACN 29.5 
? 0.1 
0.739 
? 0.019 
731.0 
? 0.0 
38.0 0.347 
? 0.038 
Chloroform 28.1 
? 0.1 
0.054 
? 0.000 
1392.0 
? 0.0 
4.8 0.548 
? 0.021 
DCM 28.8 
? 0.1 
0.058 
? 0.002 
1243.0 
? 0.0 
8.9 0.421 
? 0.018 
DMAC 36.2 
? 0.1 
0.381 
? 0.009 
877.0 
? 0.0 
37.8 1.856 
? 0.027 
DMF 37.0 
? 0.1 
0.751 
? 0.027 
887.0 
? 0.0 
37.0 0.989 
? 0.033 
DMSO 44.1 
? 0.2 
0.340 
? 0.005 
1030.0 
? 0.0 
48.0 1.992 
? 0.051 
EA 24.1 
? 0.0 
0.055 
? 0.001 
843.0 
? 0.0 
6.0 0.415 
? 0.025 
THF 27.7 
? 0.1 
0.060 
? 0.001 
830.0 
? 0.0 
7.6 0.341 
? 0.020 
* EA; ethyl acetate, THF; tetrohydrofuran; ? sourced from Smallwood and Ren et al.50,51 
 
Table 3.5 summarises the results of the measurements carried out for polymer solutions in 
selected solvents. Following polymer dissolution at low concentrations, the surface tension 
and density of the solutions appear to not change significantly compared to pure solvent, 
while both the electrical conductivity and viscosity values were found to increase (highest 
electrical conductivity was found for a solution of 5 % w/v PLGA (50:50) in DMF).  
 
The polymer type did not appear to have a significant effect on any of the parameters, with 
only the electrical conductivity of PLGA (50:50) solution being slightly less compared to 
the other two polymer types. DMSO was seen to spray the easiest and keep the most stable 
cone-jet and therefore was selected as a solvent of choice and investigated further with all 
three polymer types.  
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Table 3.5. Characteristics of the polymer solutions employed in the electrospraying 
experiments, polymer concentration at 5 % w/v (n = 6; ? SD).  
Material and 
solvent 
Surface 
Tension 
(N m-1) 
Electrical 
Conductivity 
(S m-1) 
Density 
(kg m-3) 
Viscosity 
(mPa s) 
Dielectric 
constant 
 
PLGA (50:50)  + 
ACN 
29.2 
? 0.1 
2.620 
? 0.143 
745.0 
? 0.0 
1.692 
± 0.051 
35.78 
PLGA (50:50) + 
DMF 
37.0 
? 0.1 
6.610 
? 0.054 
989.0 
? 0.0 
3.574 
± 0.034 
35.02 
PLGA (50:50) + 
EA 
24.2 
? 0.1 
0.057 
± 0.002 
854.0 
? 0.0 
1.897 
? 0.046 
5.87 
PLGA (50:50) + 
DCM 
27.1 
? 0.2 
0.105 
? 0.002 
1239.0 
? 0.0 
1.760 
? 0.052 
8.61 
PLGA (50:50)  + 
DMSO 
43.9 
? 0.1 
1.741 
? 0.076 
1036.0 
? 0.0 
5.321 
± 0.084 
45.75 
PLGA (75:25) + 
DMSO 
43.0 
? 0.9 
1.843 
? 0.044 
1039.0 
? 0.0 
5.256 
? 0.040 
45.75 
PLA + DMSO 43.3 
± 0.2 
1.843 
± 0.044 
1039.0 
± 0.0 
5.236 
± 0.045 
45.75 
 
 
Figures 3.9 – 3.12 present the results for 5 % w/v polymer solutions in DMSO. It can be 
seen that there is a trend of decreasing surface tension with increasing content of the lactic 
monomer (Figure 3.9).  
 
It is generally accepted that when electrical conductivity is below 0.01 mS m-1 a liquid 
cannot be electrosprayed due to insufficient current.52 Electrical conductivity data by Gañán-Calvo11 states that a higher electrical conductivity leads to a decrease in particle 
diameter; suggesting that PLGA (75:25) could produce particles with the smallest 
diameter.   
 
No trend was found for density (Table 3.5 and Figure 3.11); however the difference 
between all values was very small (about 0.003 g/cm3). Results of viscosity measurements 
(Table 3.5 and Figure 3.12) show that the PLGA (50:50) solution is the most viscous, with 
the PLA solution being the least. The large difference between PLGA (75:25) and PLA 
solutions suggests that polymers with decreasing glycolic acid content are less viscous. 
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Figure 3.9. Surface tension of 5 % w/v polymer 
solution in DMSO (n = 6; ± SD). 
Figure 3.12. Viscosity of 5 % w/v polymer solution in DMSO 
(continuous ramp tests, steady shear stress; n = 6; ± SD). 
 
Figure 3.11. Density of 5 % w/v polymer solution in 
DMSO (n = 6; ± SD). 
Figure 3.10. Electrical conductivity of 5 % w/v 
polymer solution in DMSO (n = 6; ± SD). 
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3.3.2. Optimisation of the main electrospray parameters 
To check the optimal applied voltage required to produce particles with the smallest 
diameter, experiments were run over a range of voltages (8.0 to 10.5 kV). The results 
(Figure 3.13) indicate that the optimal voltage for a 5 % w/v solution of polymer in DMSO 
was between 9.0 and 9.4 kV. The voltage (kV) needed to produce the smallest particle 
diameter was 9.1, 9.4 and 9.3 kV for PLGA (50:50), PLGA (75:25) and PLA respectively.  
 
 
Figure 3.13. The variation of particle size for electrosprayed 5 % w/v polymer solutions in 
DMSO with applied voltage (15 cm collection distance; 10 µL/min flow rate; n = 6; ? SD).  
 
 
3.3.3. Nanoparticle characteristics 
To observe the effect that collection distance had on the characteristics of electrosprayed 
particles, a 5 % w/v PLGA (50:50) solution in DMSO was selected as a model for spraying 
in cone-jet mode (able to produce uniform and stable particles in a continuous manner with 
a controllable jet2,53–55). Figure 3.14 shows the different spraying modes achieved with the 
model solution, with image D depicting the cone-jet mode. For this set of experiments, the 
flow rate used was 5 µL/min, and the applied voltage to obtain cone-jet mode was between 
9.0 – 9.5 kV.  
 
100150
200250
300350
400450
500550
8 8.5 9 9.5 10 10.5 11
Pa
rt
ic
le
	  D
ia
m
et
er
	  (
nm
)	  
Applied	  Voltage	  (kV)	  
PLA
PLGA(75:25)
PLGA(50:50)
	  	   58	  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Photos of various spraying modes for a 5 % w/v solution of PLGA (50:50) in 
DMSO: dripping (A), micro-dripping (B), spindle (C), and cone-jet (D).  
 
It was found that the particle diameter generally increases with decreasing collection 
distance (Figure 3.15); this could be due to instabilities within the jet, and with the fact that 
at longer collection distance there is a longer time for the solvent to evaporate. Above      
15 cm collection distance, the particle diameter no longer decreases and this could be due 
to ground electrode being too far away so jet stability is not maintained. A collection 
distance of 25 cm was also used however a stable jet could not be produced, suggesting 
there is a specific range outside which the jet loses stability.  
 
As the collection distance increases so does the zeta potential (up to a collection distance 
of 15 cm), therefore the stability of particles increases with increasing collection distance, 
when re-suspended in water (Figure 3.16). This could clarify the particle diameter results; 
at the lower collection distances there are jet instabilities when spraying and that has led to 
a less stable zeta potential value.  
 
In accordance to the Malvern definition,56 sample distribution is not too broad and is 
suitable for the use of dynamic light scattering when the PDI values are below 0.7. In these 
results all samples from a collection distance of 10 – 20 cm are below this critical value 
(indicated by thick black line). For both PLGA (50:50) and PLGA (75:25) the samples 
A B 
C D 
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collected with a collection distance of 5 cm are above this critical value showing that these 
samples are polydisperse (Figure 3.17). This again suggests that samples collected from a 
collection distance of 5 cm are electrosprayed with instabilities within the jet.  
 
Figure 3.15. The variation of particle size with collection distance for 5 % w/v polymer 
solution electrosprayed in DMSO (n = 6; ± SD; 5 µL/min; 7.0 - 7.5 kV), as measured by 
DLS (confirmed by NTA).  
 
Figure 3.16. Zeta potential of nanoparticles obtained by electrospraying 5 % w/v polymer 
solutions in DMSO (n = 6; ± SD; 5 µL/min; 7.0 - 7.5 kV).  
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 Figure 3.17. PDI of electrosprayed unloaded 5 % w/v polymers in DMSO (n = 6; ± SD) at      
5 µL/min and 7.0 - 7.5 kV, black line indicating proposed threshold for monodispersity for 
particles by Malvern. 
 
3.3.4. Preparation of nanoparticles loaded with drug surrogates 
Rhodamine B and fluorescein (Figure 3.18) were used as models to be loaded into the 
three different polymeric nanoparticles, using electrospraying as a one-step method. The 
fluorescent drug surrogates were dissolved (separately) in DMSO with the polymer and 
then electrosprayed altogether. Rhodamine B base and FITC are hydrophobic, with RB 
being insoluble in water and FITC having limited solubility. Log P values for RB and 
FITC are 6.13 and 4.90 respectively, with approximate log D values at a pH of 7.4 of 6 and 
5 respectively.57,58  
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Figure 3.18. Structures of Rhodamine B base (left) and fluorescein isothiocyanate (right).  
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The particles were collected at different collection distances to see if the effects were the 
same as those seen for unloaded particles. All polymeric solutions were electrosprayed 
using cone-jet mode with concentrations of 5 % w/v polymer and 0.5 % w/v fluorescent 
drug surrogate (concentration of the fluorescent drug surrogate was chosen at 10 % of the 
polymer concentration). Optimisation of the electrospraying parameters involved varying 
each parameter while visually checking the for jet stability. The final chosen parameters 
included: flow rate of 5 µL/min and the applied voltage to obtain cone-jet mode was 
between 7.8 – 8.2 kV. 
 
3.3.5. Characterisation of fluorescent drug surrogate solutions 
The equations at the beginning of this chapter (Equations 3.3 – 3.4) state that the particle 
diameter is inversely proportional to the electrical conductivity; therefore the data from 
Table 3.6 suggests that the particles loaded with Rhodamine B would be roughly the same 
size as those loaded with fluorescein.  
 
Table 3.6. Characteristics of polymer solutions of PLGA (50:50) in solvents with 
fluorescent drug surrogates needed for Equation 3.5, to measure estimated droplet 
diameter. 
* RB; Rhodamine B, F; fluorescein isothiocyanate.  
 
 
3.3.6. Characteristics of particles loaded with fluorescent drug surrogates 
Figure 3.19 shows an SEM micrograph of electrosprayed PLGA (50:50) nanoparticles 
loaded with Rhodamine B, showing that the particles look spherical and monodisperse.  
Solution Surface 
Tension 
(N m-1) 
Electrical 
Conductivity 
(S m-1) 
Density 
(kg m-3) 
Dielectric 
constant 
 
PLGA + 
DMSO 
43.9 
? 0.1 
0.741 
? 0.076 
1036.0 
? 0.0 
45.75 
PLGA + RB*  
+ DMSO 
44.1 
? 0.1 
19.97 
? 0.043 
1106.0 
? 0.0 
45.75 
PLGA + F*  
+ DMSO 
44.2 
? 0.2 
19.97 
? 0.241 
1150.0 
? 0.0 
45.75 
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Figure 3.19. SEM micrograph of 5 % w/v PLGA (50:50) loaded RB particles (0.5 % w/v) 
at CD of 15 cm. 
 
 
The optimal collection distance to obtain minimal size nanoparticles was found to be 
around 15 cm; additionally, longer distances were found to lead to jet instability (Figure 
3.20). This is the same as what was seen with the electrosprayed unloaded particles (Figure 
3.15). The size of the nanoparticles with fluorescent drug surrogates incorporated within 
(Figure 3.20) were smaller than those unloaded nanoparticles (Figure 3.15). This could be 
due to the addition of the drug surrogates increasing the electrical conductivity of the 
solutions (Table 3.6), which as predicted by Equations 3.3 and 3.4 decreases the particle 
diameter (inverse proportionality between particle size and electrical conductivity).      
 
For the zeta potential measurements, at a collection distance of 5 cm all the polymer 
solutions with Rhodamine B were the least stable (Figure 3.21), possibly due to the solvent 
not having evaporated so the particles clumped together. This is a similar trend as seen in 
the electrosprayed unloaded particles except for PLGA (50:50), which become less stable 
again when collected at a collection distance of 20 cm. All of the values are below 0.7 
(Figure 3.22) and therefore according to Malvern are not polydisperse. The standard 
deviation bars for PDI of electrosprayed particles loaded with Rhodamine B are larger than 
those from the electrosprayed unloaded particles. This could be expected due to the 
addition of Rhodamine B adding more variables. 
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Figure 3.20. The variation of particle size with collection distance for nanoparticles 
loaded with 0.5 % w/v RB at 5 µL/min and 7.0 - 7.5 kV (n = 6; ? SD), measured on 
Malvern and confirmed on NanoSight.  
 
 
 
Figure 3.21. ZP at various CD for PLGA (50:50), PLGA (75:25) and PLA with 0.5 % w/v 
RB at 5 µL/min and 7.0 - 7.5 kV (n = 6; ? SD).  
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Figure 3.22. PDI values for electrosprayed polymers with 0.5 % w/v RB at 5 µL/min and 
7.0 - 7.5 kV (n = 6; ? SD). 
  
When trying to collect at a collection distance of 20 cm, difficulty was found in keeping a 
stable jet for full collection duration (for both Rhodamine B and fluorescein). For samples 
loaded with either Rhodamine B or fluorescein the particle diameter was lowest when 
collected at a collection distance of 15 cm (Table 3.7), the same trend as seen with 
unloaded electrosprayed particles. Table 3.7 states than RB nanoparticles are smaller than 
FITC nanoparticles (RB 85 – 127 nm; FITC 145 – 225 nm). The stability of the jet when 
electrospraying was less stable for the FITC solution, which could affect the particle 
formation during the fission, evaporation and solidification stages (Figure 1.7), leading to 
larger particles that could agglomerate due to having solvent left within them. 
 
The zeta potential for particles loaded with Rhodamine B did not vary with change in 
collection distance; however those particles loaded with fluorescein have a lower zeta 
potential and therefore less stable at 15 cm. The zeta potential for the nanoparticles with 
fluorescent drug surrogates was more negative than the unloaded nanoparticles and this 
could be due to carboxylic acid groups present on both fluorescent drug surrogates. A zeta 
potential of ± 30 mV is desirable for a colloidal system as this is stated to be either 
strongly cationic or anionic enough to be classified as stable,59 with the higher the ZP 
(positive or negative) the more the nanoparticles will repel each other, leading to a more 
stable colloidal system, showing that the PLA nanoparticles are more stable. All the PDI 
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values are below 0.7 and the polydispersity increases with increasing collection distance 
for particles loaded with Rhodamine B and those loaded with fluorescein.  
 
The encapsulation efficiency and fluorescent drug surrogate loading values presented in 
Table 3.7 demonstrate that Rhodamine B was incorporated within the nanoparticles at a 
higher concentration than fluorescein. For both fluorescent drug surrogates, loaded 
particles the encapsulation efficiency and loading values increased with increasing 
collection distance.  
 
A good match was found between the size measurements performed on Malvern and 
NanoSight instruments. Figure 3.23 shows the particle size distribution of the Rhodamine 
B loaded particles when run on NanoSight, which show that the largest particles were 
obtained for a collection distance of 5 cm, as the bulk of the particles are furthest across 
the dot plot graph (towards the right), but with the highest intensity. 
 
Table 3.7. Electrosprayed nanoparticle characteristics for varying CD of 5 % w/v PLGA 
(50:50) in DMSO with (0.5 % w/v) fluorescent drug surrogates - RB or F (n = 6; ? SD). 
Drug 
surrogate 
loaded  
Collection 
Distance 
(cm) 
Particle 
Diameter 
(nm) 
Zeta 
Potential 
(mV) 
 
PDI 
 
Encapsulation 
Efficiency 
(%) 
Loading 
of drug 
surrogate 
(µg/mg) 
 
 
RB 
15 85.0 
± 7.2 
-25.8 
± 6.9 
0.190 
± 0.002 
65.7 
± 2.6 
61.7 
± 2.3 
10 92.0 
± 27.2 
-24.9 
± 6.4 
0.354 
± 0.012 
65.3 
± 2.0 
61.3 
± 1.9 
5 127.0 
± 17.6 
-26.7 
± 6.1 
0.365 
± 0.003 
62.9 
± 3.1 
59.2 
± 2.8 
 
 
F 
15 145.3 
± 3.3 
-19.3 
± 1.4 
0.162 
± 0.010 
38.9 
± 1.6 
37.5 
± 1.4 
10 203.2 
± 12.5 
-26.0 
± 1.1 
0.277 
± 0.032 
34.0 
± 3.2 
32.9 
± 3.1 
5 225.2 
± 30.3 
-20.9 
± 0.2 
0.332 
± 0.025 
28.4 
± 2.7 
27.6 
± 2.5 
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Figure 3.23. Nanoparticle size distribution as relative intensity plots for 5 % w/v PLGA 
(50:50) in DMSO with RB, analysed by NTA Tracking Suite 2.2, obtained for different 
collection distances: 15 cm (A), 10 cm (B) and 5 cm (C).  
 
3.3.7. EHDA equation comparative data 
The droplet size during electrospraying was determined theoretically by Gañán-Calvo11 
(using scaling laws), Equation 3.4. This along with Equation 3.5, which determines particle 
diameter from the characterisation data collected, were chosen to determine both the 
droplet and particle diameters due to them having the most experimental results backing 
them. Using the characterisation data for solvents alone (Table 3.4) an estimated droplet 
diameter could be predicted but no predicted particle diameter due to any particles being 
produced; the projected droplet diameters ranged between 400 – 540 µm. 
 
The estimated droplet diameter was smallest for acetone, acetonitrile (ACN) and 
dimethylformamide (DMF); however the evaporation that occurs between the production 
of droplets into particles will then depend on the volatility of the solvent. 
A B 
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For the characterisation data with polymers and polymer with fluorescent drug surrogate 
both an estimated droplet size and estimated particle diameter could be predicted. The 
droplet size refers to the droplet produced from electrospraying, before the processes of 
evaporation, fission, solidification and deposition could occur, which then results in the 
particles. 
 
Table 3.8. Estimated data from Equations 3.4 and 3.5 and density of the particles 
produced from electrospray (data required for Equation 3.5), for polymeric solutions at a 
concentration of 5 % w/v. 
 
Table 3.9 shows that the estimated particle diameter for the fluorescent drug surrogate 
loaded nanoparticles was roughly the same, however very small and not that likely 
obtainable. The estimated particle diameter for the loaded nanoparticles is lower than that 
of the unloaded nanoparticles (Table 3.9), which could be due to the significantly higher 
electrical conductivity. However, it is clear that the predicted values were not close to the 
actual obtained particle diameters and therefore the predictions are not accurate. This could 
Material and 
solvent 
Estimated 
droplet 
????????????? 
[Equation 3.4] 
Particle 
density 
(kg m-3) 
Estimated 
particle 
diameter (nm) 
[Equation 3.5] 
Actual particle 
diameter (nm) 
PLGA (50:50)  
+ ACN 
462.98 0.003 
± 0.002 
2.31  
- 
PLGA (50:50) + 
DMF 
398.47 0.003 
± 0.003 
1.61 - 
PLGA (50:50) + 
EA 
684.35 0.002 
± 0.002 
8.88 - 
PLGA (50:50) + 
DCM 
687.86 0.002 
± 0.002 
10.01 - 
PLGA (50:50)  
+ DMSO 
587.67 0.003 
± 0.001 
5.26 96 – 143 
PLGA (75:25) + 
DMSO 
506.86 0.002 
± 0.004 
3.83 150 – 254 
PLA + DMSO 506.28 0.002 
± 0.002 
3.82 158 – 318 
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be due to the equations being simplified resulting in other parameters affecting 
electrospraying being excluded. The applied voltage and the flow rate affects the spraying 
mode, which definitely does affect the final particle size, but are not included in the 
equations.  
 
Table 3.9. Estimated data from Equations 3.4 and 3.5 and density of the particles 
produced from electrospray for DMSO with fluorescent drug surrogates, Rhodamine B 
and fluorescein. Polymer and drug surrogate concentrations of 5.0 % w/v and 0.5 % w/v 
respectively.  
 
3.3.8. Concentration parameter data of Rhodamine B loaded particles 
Confocal micrographs were taken to show that the Rhodamine B has been incorporated 
within the particles and to observe how different concentrations and collection distances 
affect the incorporation. Figure 3.24 shows that as polymer concentration increases, above 
10 % w/v (E), particles are no longer formed, the concentration is too high and this results 
in the electrospray spluttering and producing large amount of polymer clumped together. 
At 5 % w/v (C) the particles look the most uniform and a lot smaller than at 10 % w/v, 
which was also seen in work by Enayati et al.60 It can be seen (mainly in B, C and D) that 
the Rhodamine B is incorporated into the particles; the fluorescence of the drug surrogates 
cannot be seen outside of the polymeric particles. Figure 3.25 shows that from a collection 
distance of 5 cm (A) fewer particles can be seen and the Rhodamine B looks to not just be 
encapsulated within the particles. At collection distances of 10 to 20 cm (B, C and D) 
particles can be seen with Rhodamine B incorporated within them. At 15 cm collection 
Solution Estimated 
droplet 
????????????? 
[Equation 3.4] 
Particle density 
(kg m-3) 
Estimated 
particle 
diameter (nm) 
[Equation 3.5] 
Actual particle 
diameter (nm) 
[5 – 15 cm CD] 
PLGA + 
DMSO 
587.67 0.003 
± 0.001 
5.26 96 – 143 
PLGA + RB 
+ DMSO 
342.86 0.003 
± 0.002 
1.11 77 – 144 
PLGA + F + 
DMSO 
344.96 0.003 
± 0.003 
1.15 142 – 255 
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distance (C) for both Rhodamine B and fluorescein loaded particles they looked the most 
monodispersed with the smallest particles diameter.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24. Confocal micrographs for various concentrations of PLGA (50:50) in DMSO 
with RB at a CD of 15 cm: 1.25 % w/v (A), 2.50 % w/v (B), 5.00 % w/v (C), 10.00 % w/v 
(D) and 20.00 % w/v ???????????????????????????????? 
A B 
D C 
E 
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Figure 3.25. Confocal micrographs for 5 % w/v PLGA (50:50) in DMSO with 0.5 % w/v 
RB (1) or F (2) for various CD: 5 cm (A), 10 cm (B), 15 cm (C) and 20 cm (D). Scale bar 
?????????????????? 
 
 
2A 1A 
1B 
1C 
1D 2D 
2C 
2B 
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3.3.9. Release profiles for Rhodamine B loaded particles 
Drug release from loaded nanoparticles was investigated by using UV to calculate the 
fluorescence of Rhodamine B present in PBS (pH 7.4), over the initial 6 hours of release. 
A comparison was run between PLGA (50:50) nanoparticles collected from 3 different 
collection distances: 5, 10 and 15 cm.  
 
The particles that were collected from a collection distance of 5 cm released the 
Rhodamine B the fastest over 6 hours; particles collected from 15 cm released Rhodamine 
B the slowest (Figure 3.26). This could be related to the particles at those lower collection 
distances having more DMSO still in them, leaving the particles with a more porous 
structure or less stable due to disintegration, and therefore when in solution the medium 
could get into the particles leading to a quicker Rhodamine B release. If sufficient 
quantities of DMSO were still present within the particles this could result in toxicity 
issues upon use in an application. The release seen here falls in with other research 
showing that Rhodamine B loaded PLGA particles have an initial burst release.61 
 
 
Figure 3.26. Profiles of 0.5 % w/v Rhodamine B release from loaded 5.0 % w/v PLGA 
50:50 nanoparticles electrosprayed at 5 µL/min and 7.0 - 7.5 kV, comparing the influence 
of the collection distance (n = 6; ? SD).  
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3.3.10. Optimisation of the collection method  
While the standard electrospraying protocol easily provided quantities of material that 
were sufficient for analytical purposes, larger amounts of nanoparticles were required for 
further in vitro investigations; therefore a more efficient method for particle collection was 
needed. Spraying into a solution that would allow the particles to stay dispersed without 
agglomerating was tested, and it was found that the particles produced with this collection 
method initially had a small diameter (243.3 ± 1.2) and a low PDI (0.059 ± 0.012). 
However, the particles agglomerated during the drying process and could not be re-
dispersed easily. This could have been from the DMSO and its low volatility, meaning that 
the particles still had solvent in them so on re-dispersion they may swell and clump 
together. A change of solvent could help overcome this issue.  
 
Acetonitrile was considered as a new solvent due to it electrospraying easily when 
combined PLGA (50:50), also shown to be successfully used in literature.1,62 The results 
obtained from spraying with ACN as the solvent, had the lowest particle diameter at a 
collection distance of 15 cm (Table 3.10). The high standard deviation for the particle 
diameter for those samples with higher collection distances suggest that the jet was not 
stable while electrospraying which explains the high PDI values for those samples. DOX 
was not fully soluble in ACN so therefore a different solvent is required for future 
experiments. The limited solubility of DOX in ACN could also explain the high PDI 
values of all the particles sprayed with ACN.  
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Table 3.10. PLGA (50:50) in ACN electrosprayed into ultrapure water at 10 µL/min  
(n = 3; ? SD). 
Collection Distance 
(cm) 
Particle Diameter 
(nm) 
PDI 
25 280.7 
? 43.1 
0.482 
? 0.080 
20 257.0 
? 27.1 
0.359 
? 0.063 
15 215.6 
? 7.4 
0.407 
? 0.046 
15 (re-dispersion after 
freeze drying) 
201.0 
? 6.5 
0.409 
? 0.027 
 
DCM was chosen as a new solvent to try due to its very high volatility; this could possibly 
lead to particles with smaller particle diameters as the DCM could have all have 
evaporated off within the 15 cm collection distance. A smaller needle was experimented 
with the expectation of decreasing the particle diameter and as expected the needle with 
the smaller diameter produced smaller particle diameters and a lower PDI (Table 3.11). For 
the purpose of increasing the yield of nanoparticles, a higher flow rate was experimented 
with (15 µL/min) and it was seen that this did not have a significant effect on the particle 
diameter (Table 3.12) and therefore 15 µL/min was used as the new flow rate along with a 
Teflon cylinder to help increase yield by guiding all the particles into the collection dish.  
 
Table 3.11. Particle diameter and PDI values for 5 % w/v PLGA (50:50) in DCM at a 
collection distance of 15 cm, filtered before measurements (0.45 µm) (n = 3; ? SD).  
 
 
Needle Size 
(inner diameter, µm) 
Particle Diameter (nm) 
 
PDI 
 
750 294.6 
± 16.50 
0.328 
± 0.033 
400  238.2 
± 7.850 
0.150 
± 0.119 
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Table 3.12. Comparison of particle characteristics from EHDA sprayed PLGA (50:50) in 
DCM at two different flow rates (n = 3; ? SD).  
 
 
  
 
Parameters 
Flow Rate (µL/min) 
5 15 
AV needed to achieve a 
stable cone-jet 
7.8 kV 
 
8.0 kV 
Mean Particle Diameter 
(nm) 
172.8 
? 4.1 
188.3 
? 8.4 
Mean PDI 
 
0.259 
? 0.0 
0.171 
? 0.0 
Mean Zeta Potential  
(mV) 
-38.2 
? 1.1 
-37.7 
? 0.8 
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3.4. Conclusions 
 
The characterisation data put into Equations 3.5 and 3.7 showed estimated particle 
diameters, which were very small and did not match up to the actual particle diameters that 
were measured on the particle sizers for those electrosprayed nanoparticles. This is most 
likely due to simplification of the equations resulting in essential parameters affecting 
EHDA being excluded.   
 
Electrospraying was employed to produce nanoparticles with a minimum particle diameter 
by optimising the parameters used for electrohydrodynamic atomisation, especially the 
collection distance. Another parameter that was investigated and optimised was the applied 
voltage, which at a collection distance of 15 cm showed to produce minimal particle 
diameter, within a range of 9.1 – 9.4 kV. The optimal concentration to produce uniform, 
monodispersed nanoparticles was seen under confocal microscopy to be 5 % w/v. These 
particles were then loaded with Rhodamine B and fluorescein (separately), with the 
loading value for Rhodamine B being twice as high as fluorescein. Log P values are 6.13 
for RB base and 4.90 for FITC and log D values at a pH of 7.4 are approximately 6 and 5 
for RB and FITC respectively.57,58 RB is more hydrophobic than FITC so when combined 
with the hydrophobic polymers in water the higher hydrophobicity of RB leads to more 
grouping together with the polymer due to them liking the same environment (the affinity 
of the polymer and dye). Confocal micrographs showed that the dyes had been 
incorporated within the particles.   
 
For both the unloaded and the loaded particles a collection distance of 15 cm produced 
particles with the smallest particle diameter and the most stable in solution, due to having 
the most stable zeta potential and the lowest PDI values. Although for the nanoparticles 
loaded with Rhodamine B there was no trend seen for PDI and collection distance and the 
zeta potential became less stable as the collection distance increased to 20 cm. For all three 
polymers when electrosprayed the optimal applied voltage to produce particles with the 
smallest particle diameter ranged between 9.1 – 9.4 kV.  
 
For the purpose of increasing particle production and yield, other collection methods were 
investigated and it was found that changing the solvent to DCM, with its high volatility, 
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lead to particles with a small diameter when collected for a longer duration. To increase 
the yield an increase in flow rate was investigated (5 to 15 µL/min) which was showed to 
not significantly impact the mean particle diameter, zeta potential or PDI values. The 
diameter of the needle was also shown to have an effect on the diameter of the particles 
produced, a lower needle diameter leading to smaller particle diameters.  
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4. Studies of doxorubicin loading and release from folic 
acid functionalised PLA/PLGA nanoparticles 
 
4.1. Introduction 
This chapter presents the results of work carried out with the aim to produce nanoparticles 
loaded with both doxorubicin and folic acid using EHDA as a one-step method. The loaded 
nanoparticles were optimised for minimal particle diameter and then characterised for drug 
loading, PDI and zeta potential values; drug loading and release behavior were investigated 
using fluorescence spectroscopy and HPLC.  
 
4.1.1. PLA/PLGA nanoparticles as carriers for anticancer drugs 
PLA and PLGA are suitable for the fabrication of nanocarriers that can be used in a wide 
range of applications, the delivery of chemotherapeutic agents being a key one due to the 
established biocompatibility and biodegradability of these materials, as well as their ability 
to sustain and control drug release, cross physiological barriers, facilitate extravasation into 
tumors and reduce drug side effects.1–4  
 
Several common anticancer agents loaded within PLA/PLGA nanocarriers are presented in 
Table 4.1, and some nanoformulations have been tested in vitro and in vivo and then 
progressed onto clinical trials. However, many of the nanocarrier systems investigated 
showed increased cytotoxic effects compared to the free drug or even to the current basic 
formulation. Dual applications of these nanostructures (such as coupling anticancer 
treatment with magnetic resonance imaging) have been considered. 
 
4.1.2. Doxorubicin as a chemotherapeutic agent 
Chemotherapeutic agents are known to destroy cancer cells along with normal, healthy 
cells therefore causing side effects that can include nausea, fatigue, hair loss and an 
increased risk of infection. Due to the many side effects associated with current 
chemotherapeutic agents, targeted systems which are able to deliver chemotherapeutic 
agents selectively to tumour cells (thereby limiting the negative effects to healthy cells) 
represent a priority area of research.  
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Table 4.1. Examples of anticancer agents loaded within PLA and PLGA based nanoparticles. 
 
Polymer Drug Details and Findings References 
 
 
 
PLA 
 
 
Paclitaxel MPEG nanoparticles were compared to Taxol for their in vitro cytotoxic effect on breast cancer cells, showing to 
be over 10 times more cytotoxic.  
5 
 
Docetaxel Loaded PLA-TPGS nanoparticles had a significantly higher cytotoxic effect (in vitro) than the current Docetaxel 
clinical formulation (Taxotere) at the same dosage.   
6 
 
Docetaxel PLA-PCL nanoparticles were successfully produced for the encapsulation of Docetaxel. 7 
Paclitaxel Block copolymer of PLA-TPGS star-shaped nanoparticles loaded with paclitaxel with produced for the treatment 
of breast cancer. In vitro and in vivo studies were undertaken with positive results. 
8 
 
 
 
 
 
 
 
PLGA 
 
Paclitaxel 
PLGA nanoparticles loaded with paclitaxel produced and strongly enhanced the cytotoxic effect of the drug 
compared to Taxol alone. Tested on various human cell lines and in vivo experiments showed efficacy on liver 
tumours in mice and model glioblastoma tumours. 
 
9–13 
 
 
Paclitaxel 
Paclitaxel loaded PLGA-based nanoparticles with iron, for dual cancer therapy and MRI. Results showed that 
there was significant cellular uptake of nanoparticles into CT26 cells, with paclitaxel having a cytotoxic activity 
and the loaded iron showing no toxicity. 
 
14 
Doxorubicin Multifunctional PLGA nanoparticles were synthesised with DOX being successfully released and sustained for 
three weeks. In vitro cytotoxicity seen against human breast cancer and liver carcinoma cells, with in vivo 
pharmacokinetics evaluated in female rats. 
 
15–19 
Cisplatin PLGA-PEG nanoparticles for the treatment of prostate cancer, by targeting prostate-specific membrane antigen.  19–22 
Etoposide Loaded into PLGA with Pluronic F68 for efficient cancer therapy, in vivo studies in mice and rabbits undertaken 
to look at biodistribution and pharmacokinetics. 
23 
Curcumin Encapsulated in nanoparticles was proven to improve oral bioavailability of curcumin and was effective against 
prostate, breast and metastatic ovarian cancer cells. 
24–27 
*MPEG; methoxy polyethylene glycol, MRI; magnetic resonance imaging, CT26; mouse colon carcinoma cells.
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Doxorubicin (DOX) is a successful chemotherapeutic agent usually administered to 
advanced cancer patients but the side effects can be severe. In clinical settings, DOX has 
been widely used for a variety of cancers and it has been shown to successfully induce 
tumour regression in acute leukemia, lymphomas, soft-tissue and osteogenic sarcomas, 
pediatric malignancies and adult solid tumours including breast, lung, stomach, thyroid; it 
has been also extensively studied in advanced ovarian cancers.28,29 DOX has shown anti-
tumour activity against cervix carcinoma, it is widely used in the treatment of gastric and 
thyroid malignancies, and represents the main treatment for advanced neoplasms such as 
breast cancer and sarcomas.30 
 
DOX (Figure 4.1) was discovered in the 1960s and is a member of the cytotoxic 
anthracycline antibiotics group; it is isolated from Streptomyces strains and is one of the 
most effective anticancer drugs in use today. Several researchers have tried to improve the 
therapeutic activity of DOX by allowing delivery of a higher dose to the tumour tissue only 
and by attempting to lower the side effects.31–36  
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Figure 4.1. Structures of Rhodamine B (A), FITC (B) and DOX (C): an amino-sugar 
daunosamine is linked through a glycosidic bond to the C7 of a tetracyclic aglycone 
(doxorubicinone); the phenolic groups contribute acidic function, while the sugar amino 
group adds basicity, making the molecule amphoteric.37  
 
A	  
B	   C	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DOX is currently available in two injectable formulations, namely as a simple solution and 
a more complex liposomal formulation. Both are given by injection into a fast-running 
infusion, however they are different in their doses and licensed indications and cannot be 
used interchangeably.38 The brand names for liposomal DOX are: Caelyx, Myocet or Doxil. 
Pegylated liposomal DOX can be used to treat advanced ovarian cancer for those patients 
that are allergic to platinum compounds.39 
 
DOX works by interacting with the DNA double helix and interferes with the nucleic acid 
synthesis. It produces a marked cytotoxic effect on cells when in the S phase, due to 
intercalation that inhibits nucleotide replication and the actions of DNA and RNA 
polymerases. This includes inhibition of the synthesis of macromolecules and generation 
of free radicals that can result in DNA damage or lipid peroxidation, DNA binding and 
alkylation, DNA cross-linking, interface with DNA unwinding or DNA strand separation, 
helicase activity and direct membrane effects.40,41 DOX also affects cells via a second 
mechanism, namely enzyme inhibition, by binding and inhibiting topoisomerase II and 
preventing transcription.42 The DNA damage is followed by G1 and G2 growth arrest and 
induction of apoptosis, as it has been proposed in order to correlate with tumour response 
and patient’s outcome.43 
 
The primary metabolism of DOX occurs in the liver, where the drug is converted into its 
major metabolite (doxorubicinol) via an enzymatic reaction that involves nictotinamide 
adenine dinucleotide phosphate-dependent aldoketoreductase.44 The elimination of DOX 
and its metabolites predominantly occurs via the hepatobiliary pathway. After treatment, 
more than 50 % of the drug is excreted in bile within 7 days; the rest of the drug is 
excreted in faeces, about 10-20 % and 40-50 % within 24 and 150 hours respectively. 
Clearance of DOX by the renal system is low; only about 12 % of the total dose was 
recovered in urine during 6 days post-treatment.45 
 
4.1.3. Targeted drug delivery 
Targeted drug delivery systems aim to improve drug efficacy while reducing the toxicity of 
chemotherapeutics, thus allowing powerful anticancer agents to be administered without 
the patient becoming ill from the side effects. A number of approaches for targeted 
delivery to cancer cells have been investigated, and several specific receptors (targets) 
	  	   87	  
have been identified; various moieties can therefore be added to a drug delivery system to 
impart targeting properties (Table 4.3). 
 
 Table 4.3. Examples of receptors and active targeting agents.  
Tumour 
cell type 
Receptor Targeting 
agent 
Findings/Outcomes Reference 
B 
lymphoma 
CD74 
receptor 
Anti-CD74 
antibody, 
LL1 
Liposomes with ligand covalently 
attached; selectivity towards B 
lymphoma cells.  
 
46 
 
 
 
 
B 
lymphoma  
 
 
 
BAFF 
receptor 
 
 
 
mBAFF* 
BAFF is an endogenous ligand for the 
BAFF receptor and mBAFF is a 
soluble mutant form of BAFF, where 
the amino acids 217-224 are replaced 
with two glycine residues that can bind 
to BAFF receptors. PEGylated 
liposomes have been produced for in 
vitro targeting.  
 
 
 
47 
 
 
 
HT-29 
 
 
Hyaluronan 
receptors 
 
 
HA*  
Some cancer cell lines such as HT-29 
overexpress these receptors; chitosan 
nanoparticles loaded with an anti-
cancer drug (5-flurouracil) and 
decorated with HA showed higher 
cytotoxicity in vitro toward HT-29 
cells compared to nanoparticles 
without HA. 
 
 
 
48 
 
 
 
Hepatoma 
 
ASGP 
receptors* 
 
 
Galactose 
Hepatoma cells overexpress ASGP 
receptors and dextran-based polymeric 
micelles have been used in vivo to 
target liver cancer with significant 
results.  
 
 
49 
 
 
Molt-4 
leukemia  
 
TfR* 
TfR-
targeting 
peptide  
For the anti-cancer drug artemisinin 
conjugation to the TfR-binding peptide 
can improve the potency and 
selectivity of the drug significantly.  
 
 
50 
 
*mBAFF, mutant B cell activating factor belonging to the TNF family; HA, hyaluronic 
acid; HT-29, colon adenocarcinoma cell line; ASGP, asialo glycoprotein; TfR, transferrin-
receptor. 
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4.1.4. Folic acid in targeting cancer 
Previous research has shown that some human cancer cells (including ovarian, lung, 
colorectal and breast) overexpress folate receptors on their surface,51–57 so folic acid can be 
attached to the surface of drug delivery system to increase their selectivity toward tumour 
cells (Figure 4.2). Folates and their drug conjugates can enter cancer cells using receptor-
mediated endocytosis, thus bypassing the normal permeability barriers that would limit the 
entry of many drugs; t????-carboxyl group on folic acid binds to the folate receptor, with 
equal affinity as free folic acid.58  
 
 
Figure 4.2. A schematic of the receptor-mediated endocytotic mechanism of drug delivery 
for a folate-conjugated active (adapted from 59).  
 
Folic acid (Figure 4.3) represents the synthetic form of folates and is used in many fortified 
foods and vitamin supplements. It is a B vitamin and is indispensable for DNA replication, 
nucleotide biosynthesis, methyl group supply, as well as in cell repair and growth.60 
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Table 4.4. Literature reports of folic acid being investigated as targeting agent for cancer cells.  
Cancer cell line Delivery system Outcomes of study References 
Fibroblasts 
(KCLB) 
Folate-mediated copolymeric nanospheres (mPEG 
and PCL) prepared by synthesising block 
copolymers and incorporating amino groups as a 
drug carrier for paclitaxel. 
Confirmation by particle surface analysis showed that FA 
was, in some parts, exposed on the surface. In vitro 
results showed lower cytotoxicity compared to free drug 
but no studies were undertaken to directly look at 
targeting capabilities.  
 
 
61 
Oral carcinoma 
(KB) 
FA was covalently conjugated to liposomes via 
spacers. 
Free FA was added to KB cells before the liposomes 
were incubated and this inhibited their uptake, suggesting 
that uptake occurs by folate endocytosis pathway. 
 
62 
Lung tumour 
(M109) 
Folate targeted liposomes (polyethyleneglycol-
derivatised distearoyl-phosphatidylethanolamine) 
loaded with DOX. 
In vitro studies proved folate modified liposomes to be 
more effective compared to free DOX and non-targeted 
liposomes.  
 
63,64 
Oral carcinoma 
(KB) 
PLGA-PEG folate receptor targeted micelles 
loaded with DOX. 
Significantly higher cellular uptake into cells compared 
to free DOX and DOX micelles; enhanced cellular 
uptake, assumingly due to folate-receptor mediated 
endocytosis. 
 
65,66 
Leukaemia cells 
KG-1 & L1210JF 
(FR+) 
KG-1A & L1210 
(FR-) 
FR-targeted liposomes were loaded with DOX. For both the FR positive cell lines the targeted liposomes 
were significantly more cytotoxic than normal liposomes. 
For the FR negative cell lines, no significant difference 
was seen, suggesting that the folic acid did have targeting 
capabilities. 
 
 
67 
C6 glioma MPEG/PCL amphiphilic copolymer nanospheres 
coupled to folic acid and loaded with paclitaxel.  
C6 glioma cells have low levels of FR expression 
however a significant difference was observed for DOX 
uptake/delivery into the cells from the targeted liposome 
conjugates (compared to non-FA modified DOX 
liposomes).  
 
 
68 
*MPEG, methoxy poly(ethylene glycol); PCL, polycaprolactone; FR, folate receptors. 	  	   90	  
Using folic acid to target folate receptors on cancerous cells has been utilised already and 
examples of this can be seen in Table 4.4. Generally research has focused on loading 
liposomes with an anti-cancer drug to target cancer cells overexpressing folate receptors.  
 
4.1.5. HPLC - method validation 
When incorporating actives within a delivery system, analytical methods such as 
spectroscopy or chromatography are commonly employed to accurately measure their 
concentration. HPLC is a fast, precise, reproducible and convenient technique for 
concomitant detection of several actives within a sample; therefore it was the method of 
choice for simultaneously quantifying the amount of both drug and targeting agent in this 
work. The modern HPLC technique originated in the mid-1960s and has been found to 
have many applications in organic, inorganic and biochemical research areas. HPLC 
instruments can detect different compounds in a sample by separating them on a 
chromatographic column and eluting them off at different times, depending on their 
affinity to the stationary phase. The mobile phase/s are pumped continuously under a 
specified flow rate and the sample is introduced into the flow that carries it along the 
column that contains the stationary phase. The separated compounds are detected and their 
concentration can be calculated.  
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4.2. Experimental details 
 
4.2.1. Materials 
All solvents (HPLC grade) were purchased from Fisher Scientific (Loughborough, UK), 
and DOX hydrochloride was purchased from LGM Pharma (USA).  
 
4.2.2. DOX base extraction  
A solution of DOX hydrochloride (25 mg) in ultrapure water (10 mL) was extracted (3 
times) in a separating funnel with dichloromethane (DCM) following the addition of 
several drops of dilute ammonia. The combined organic extract was dried overnight on 
anhydrous magnesium sulfate and filtered, DCM was removed using a rotary evaporator 
and the resulting DOX base was further dried overnight in a desiccator.   
 
4.2.3. Solution preparation and characterisation 
Polymers (PLGA (50:50); PLGA (75:25); and PLA) were dissolved separately in DCM 
and the solutions (9 mL; polymer 5 % w/v) were magnetically stirred for 30 minutes (600 
rpm) at room temperature. A solution of DOX and folic acid in DMSO (1 mL) was added 
and stirred for a further 30 minutes (the final ratio of solvents DCM:DMSO was 9:1 vol).  
 
All prepared solutions were characterised in terms of surface tension, electrical 
conductivity, density and viscosity, as described in section 3.2.1, with the viscosity 
measurements run as a Newtonian liquid with continuous ramp tests. All characterisation 
measurements were run in triplicate. 
 
4.2.4. Polymer characterisation – FTIR 
Infrared spectra were recorded using a Thermo Nicolet Nexus Euro instrument (Minnesota, 
USA) equipped with an ATR Smart Orbit accessory with diamond crystal (range 400 – 
4000 cm-1); all samples were analysed as fine powders.  
 
4.2.5. Electrohydrodynamic processing 
Experiments were run as stated in section 3.2.4 employing voltages between 9.2 – 9.6 kV; 
a ???? ?? diameter needle was used and the optimisation procedure was repeated. 
Electrosprayed samples were collected in a Petri dish with a Teflon cylinder set up (Figure 	  	   92	  
4.4) to minimise sample loss. The nanoparticle characterisation measurements were run as 
previously described in section 3.2.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Single needle EHDA set up contained in an earthed box for safety, with a 
Teflon cylinder modification to minimise nanoparticle loss; the high voltage power supply 
is outside the box (not seen in the figure). 
 
 
4.2.6. HPLC analysis 
Samples were analysed using an Agilent 1100 Series instrument (Agilent Technologies, 
Santa Clara, California, USA) equipped with a Luna C8 (150 x 4.6 mm) column with 5 µm 
particles, ??? ??? ??? using ??? ?????????? ??????? ??? ???? ?? and a flow rate of 1mL/min. 
Samples were run on a gradient with two mobile phases as detailed in Table 4.5; the run 
time was 17 minutes in total, with the final minute used to equalise the mobile phase back 
to the starting conditions. Both DOX and folic acid were analysed using a diode array 
detector, set for 254 nm (DOX) and 290 nm (folic acid); DOX concentration was also 
measured using an on-line fluorescence detector (excitation 480 nm; emission 550 nm).  
Syringe	  pump	  
Sample	  collector	  
with	  Teflon	  cylinder	  
Collection	  
distance	  
Capillary	  
needle	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Table 4.5. Mobile phase constitution and gradient used for the HPLC analysis (release 
profile studies).   
 
 
 
 
 
 
 
 
 
 
4.2.7. Determination of encapsulation efficiency and drug loading  
Electrosprayed nanoparticles (2 mg) were dissolved in DMSO and analysed with HPLC. 
Encapsulation efficiency (EE) was calculated using the Equation 4.1 and the drug loading 
(DL) was calculated using Equation 4.2.  
 
 
 
 
4.2.8. Particle density measurements 
Dried nanoparticles (5 mg) were introduced in a pycnometer (10 mL) that was filled with 
water and weighed; the difference in weight compared to that of the pycnometer with 
water alone (without displacement by nanoparticles) allowed the calculation of the density 
of nanoparticles.  
 
 
 
 
Time	  
(min)	  
Mobile	  Phase	  A	  –	  
H2O	  +	  0.06	  %	  TFA	  
Mobile	  Phase	  B	  –	  
ACN	  +	  0.06	  %	  TFA	  0.00	   80.0	  %	   20.0	  %	  5.00	   80.0	  %	   20.0	  %	  6.00	   65.0	  %	   35.0	  %	  16.00	   65.0	  %	   35.0	  %	  17.00	   80.0	  %	   20.0	  %	  
Equation 4.1 EE (%) = x 100 
Amount of drug present 
Amount of drug initially 
loaded 
DL (µg/mg) = x 100 
Amount of drug 
Amount of drug and  
polymer 
Equation 4.2 
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4.2.9. AFM investigations 
Dried nanoparticles were placed on freshly cleaved muscovite mica (Agar Scientific, Essex, 
UK) that was mounted on a nickel disc (diameter 1 cm) with double-sided adhesive tape; 
unattached nanoparticles were removed using a stream of N2. AFM studies were carried 
out using a MultiMode/NanoScope IV Scanning Probe Microscope (Digital Instruments, 
Santa Barbara, CA, USA), in air, under ambient conditions (T = 23 °C, RH = 21 %). 
Scanning was performed using the J-scanner (max. xy = 200 ?m) in contact mode, using 
Si3N4 cantilevers with integrated tips (Probe D, Bruker Instruments, France). Images were 
subsequently processed using NanoScope Analysis software (v1.4, Bruker, Santa Barbara, 
USA). 
 
4.2.10. Release studies 
Samples of freeze dried nanoparticles loaded with DOX and folic acid were re-suspended 
in PBS (0.5 mg/mL) by sonication and vortexing (1 minute each) and then incubated in a 
shaking water bath (37 °C). At predetermined time points, samples were removed and 
centrifuged (7,500 rpm; 9,978 g; 5 min) before being fil???????????????and the supernatant 
frozen before being analysed by HPLC using an autosampler as described in section 4.2.6.  
 
4.2.11. Statistical analysis 
The statistical analysis was performed using IBM SPSS statistics 22 software (Armonk, 
New York); the results were checked for normal distribution using normality plots then 
statistical significance was tested using one-way analysis of variance (ANOVA) followed 
by post hoc Tukey test (p values set at 0.05), as described in Chapter 3. 
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4.3. Results and discussion 
Unless otherwise stated, the results presented in this chapter were obtained with 
nanoparticles that were produced using the following parameters: 5.0 % w/v polymer 
loaded with DOX at 0.5 % w/v and folic acid at 0.1 % w/v, collected at a distance of 15 cm. 
The DOX concentration was the same as the concentration of the fluorescent drug 
surrogate (at 10 % of the polymer concentration). 
 
4.3.1. Characterisation of DOX and FA solutions for EHDA 
Characterisation measurements were carried out first for the solutions to be electrosprayed 
in order to verify their suitability for the technique, in an attempt to predict droplet and 
final particle diameters. Table 4.6 summarises the characterisation data obtained for 
complex solutions of polymer, folic acid and DOX and shows this data in the correct units 
and format to be applied to Equation 3.4, which estimates the droplet and final particle size 
for operation in cone jet mode. The dielectric constant values needed for Equation 3.4 were 
obtained from literature, as described in detail in Chapter 3. The contribution of both folic 
acid and doxorubicin to the estimated dielectric values tabulated in Table 4.6 was 
considered negligible as FA and DOX concentration was very small (0.6 % w/v combined).  
 
Table 4.6. Characteristics of solutions of polymers (5 % w/v) in solvents with FA and DOX 
needed for equation 3.4 to calculate an estimated droplet diameter. 
 
 
 
 
 
 
 
 
 
 
 
 
Polymer in 
solution  
Surface 
Tension  
(N m-1) 
Electrical 
Conductivity  
(S m-1) 
Viscosity 
(mPa s) 
Density 
(kg m-3) 
Dielectric 
constant 
 
PLGA 
(50:50) 
28.4 
? 0.0 
14.76 
? 0.04 
2.965 
? 0.048 
1227.0 
? 0.0 
8.61 
PLGA 
(75:25) 
30.4 
? 0.1 
14.82 
? 0.13 
2.879 
? 0.094 
 1224.0 
? 0.0 
8.61 
PLA 31.1 
? 0.1 
14.89 
? 0.08 
2.877 
? 0.082 
1222.0 
? 0.0 
8.61 
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The estimated values for particle diameter appear similar for all three types of polymeric 
nanoparticles, however it can be noticed that the estimated particle diameter decreases with 
increasing PLA content, Table 4.7.  
 
These estimated particle diameters are very small, yet they are bigger than the estimated 
particle diameters for the dye loaded nanoparticles from Chapter 3, (approximately 2.2 nm 
for the DOX and folic acid particles and 1 nm for dye loaded). This could be because with 
an increase in electrical conductivity of a solution results in a decrease in the estimated 
particle diameter; the solution containing only DMSO and polymer had the lowest 
electrical conductivity with the largest estimated particle diameter of 5.26 nm.  
 
The higher the electrical conductivity of a solution, the higher the applied voltage required 
to obtain a stable cone jet, and the smaller the particle diameter.  
 
Table 4.7. Estimated data from Equations 3.4 and 3.5 and density of the particles 
produced from electrospray. 
 
 
 
 
 
 
 
 
 
 
 
4.3.2. DOX loading - optimisation experiments 
To produce a delivery system with maximum drug loading but minimal particle diameter, 
different concentrations of DOX in the electrosprayed solution were tested; it was found 
that increasing the DOX concentration did not have a significant effect on the particle 
diameter (Table 4.8), therefore the highest DOX concentration was used in further studies. 
The DOX concentration was also kept the same as that used for the fluorescent drug 
surrogates.  
Polymer in 
solution  
Estimated droplet 
????????????? 
[Equation 3.4] 
Particle density  
(kg m-3) 
Estimated particle 
diameter (nm) 
[Equation 3.5] 
PLGA 
(50:50) 
425.63 0.003  
± 0.002 
2.31 
PLGA 
(75:25) 
420.37 0.003  
± 0.003 
2.22 
PLA 418.34 0.003  
± 0.002 
2.18 
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When investigating post-electrospraying processing conditions, it was found that both the 
particle diameter and the PDI values were not affected by freeze-drying (Table 4.9). The 
slight bimodal distribution observed could be due to free (not loaded) DOX because of its 
low solubility in PBS.  
 
Table 4.8. Particle diameters from electrosprayed 5 % w/v PLGA (50:50) in DCM with 
DOX (n = 6; ? SD). 
 
Table 4.9. Nanoparticle characteristics as measured by DLS (Malvern) for a solution of 
5.0 % w/v PLGA (50:50) in DCM with 0.5 % w/v DOX (without filtration) collected in 
ultrapure water, with % being indicative of bimodal size distribution (n = 6; ? SD).  
 
*	  following redipersion by vortexing (1 min) and sonication (5 min) 
 
4.3.3. Characteristics of electrosprayed nanoparticles loaded with both DOX and FA  
The particle diameter was found to decrease with collection distance up to about 15 cm, 
which could be due to an increase in the stability of the jet as the collection distance 
increased to 15 cm, above which there was a dramatic increase in size (Figure 4.5). A 
similar trend was observed for particles loaded with Rhodamine B (Figure 3.13), however 
without a noticeable size increase. Such a difference could be explained by a higher 
electrical conductivity of the solution containing DOX, which could lead to jet instability 
DOX  
Concentration (w/v) 
Mean Particle Diameter 
(nm) 
Mode Particle Diameter 
(nm) 
0.2 % 106.1 
? 8.9 
93.0 
? 10.6 
0.5 % 100.2 
? 7.7 
86.0 
? 16.9 
Sample Measurement  Particle Diameter 
(nm) 
PDI 
Before  
freeze drying 
274.1 ? 12.0 (92.7 %) 
66.02 ? 13.7 (7.3 %) 
0.460 ? 0.026 
After  
freeze drying* 
268.6 ? 3.0 (81.0 %) 
78.1 ? 4.0 (19 %) 
0.411 ? 0.019 
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at longer collection distances. To ensure the smallest particle diameter possible, a 
collection distance of 15 cm was always used in further experiments. 
 
Figure 4.5. Size of electrosprayed DOX and FA loaded nanoparticles (PLGA (50:50), 
PLGA (75:25) and PLA; filtered 0.45µm) at different collection distances (n = 6; ? SD). 
 
Table 4.10. Characteristics of DOX-loaded nanoparticles and DOX- and FA-loaded 
nanoparticles, both electrosprayed in DCM (n = 6; ± SD; collection distance 15 cm).   
Electrospray 
solution 
Particle 
diameter 
(nm) 
Estimated particle 
diameter (nm) 
[Equation 3.5] 
Zeta potential 
(mV) 
PDI 
PLGA (50:50) + 
DOX 
88.6 
± 5.7 
2.31 - 28.7 
± 2.5 
0.307 
± 0.005 
PLGA (50:50), 
DOX + FA 
90.7  
? 8.0 
2.31 - 25.4 
± 2.4 
0.326 
± 0.008 
PLGA (75:25) + 
DOX 
104.7 
± 13.6 
2.22 - 26.0 
± 4.7 
0.488 
± 0.014 
PLGA (75:25), 
DOX + FA 
105.7 
? 11.0 
2.22 - 20.5 
± 5.9 
0.568 
± 0.018 
PLA + DOX 92.5 
± 2.8 
2.18 - 30.9 
± 2.4 
0.301 
± 0.006 
PLA, DOX  
+ FA 
94.3 
? 3.0 
2.18 - 26.9 
± 2.9 
0.371 
± 0.008 
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Table 4.10 compares the characteristics of the electrosprayed particles loaded with DOX to 
those loaded with both DOX and FA. The reduction in the negative values of the zeta 
potential results suggest that some of the folic acid is likely present on the surface of the 
nanoparticles.69 As expected, for all three types of polymeric nanoparticles, the particle 
diameter increased following addition of folic acid. 
 
The drug loading characteristics of the electrosprayed particles (using 0.5 % w/v DOX and 
0.1 % w/v FA) are presented in Table 4.11. The PLA nanoparticles have the highest 
loading of folic acid (almost twice as much compared to that in particles of PLGA (50:50) 
and (75:25)), however PLGA (75:25) nanoparticles have the highest loading of DOX. The 
higher amount of folic acid (stronger association via the amino groups present) and less 
DOX loaded in the PLA nanoparticles could be due to its decreased hydrophilicity 
compared to PLGA. PLGA (75:25) was the most difficult to spray because of jet stability 
problems over long periods of time, which led occasionally to particles clumping together; 
these particles were generally easy to re-disperse but they required a longer sonication time 
compared to the PLGA (50:50) and PLA based nanoparticles.  
 
Table 4.11. Characteristics of electrosprayed particles, using 5.0 % w/v polymer, 0.5 % 
w/v DOX and 0.1 % w/v FA (n = 6; ± SD).  
 
 
 
 
 
  
Polymer 
Type 
Loading 
of FA 
(µg/mg) 
Loading 
of DOX 
(µg/mg) 
Encapsulation 
Efficiency for 
FA (%) 
Encapsulation 
Efficiency for 
DOX (%) 
PLGA 
(50:50) 
1.6  
? 0.2 
48.9  
? 1.0 
8.7 
? 1.1 
54.7  
? 1.1 
PLGA 
(75:25) 
1.6  
? 0.1 
55.8  
? 4.0 
8.8 
? 0.0 
62.5  
? 4.4 
PLA 3.1  
? 0.4 
47.2  
? 3.4 
17.3  
? 2.2 
52.9  
? 3.8 
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4.3.4. FTIR characterisation of FA and DOX loaded particles 
To investigate the structure and composition of the electrosprayed loaded nanoparticles, 
FTIR was also employed in an attempt to detect the loaded actives.  
 
 
Figure 4.6. FTIR spectra of pure PLGA (50:50), DOX, FA and PLGA (50:50) 
electrosprayed nanoparticles loaded with both DOX and FA (NPs). 
 
 
As folic acid is present in a very small amount in the loaded nanoparticles, it was not 
unexpected that it could not be clearly identified in the FTIR spectra; the presence of DOX 
however was evidenced for all three types of loaded nanoparticles (Figures 4.6 to 4.8) by 
the distinctive band at 950 cm-1, attributed to the O–H bending vibration in carboxylic 
acids. 
Wavelength cm-1 
DOX	  
FA	  
PLGA	  (50:50)	  
NPs	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Figure 4.7. FTIR spectra of pure PLGA (75:25), DOX, FA and PLGA (75:25) 
electrosprayed NPs loaded with both DOX and FA.  
 
 
 
Wavelength cm-1 
DOX 
FA 
PLGA 
(75:25) 
NPs 
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 Figure 4.8. FTIR spectra of pure PLA, DOX, FA and PLA electrosprayed NPs loaded with 
DOX and FA. 
 
 
4.3.5. AFM investigations of particles loaded with DOX and FA 
Large scale AFM images of dried nanoparticle agglomerates, representative for all three 
types of polymers, are presented in Figure 4.9. DOX and folic acid loaded nanoparticles 
with size around 100 nm, as measured by DLS and NTA (Table 4.10), tend to agglomerate 
when in a dry state though the individual particles are still noticeable; these agglomerates 
are easily re-dispersible in water and PBS (pH 7.4) by sonication.  
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Figure 4.9. AFM micrographs of electrosprayed particles loaded with DOX and FA for: 
PLGA (50:50) (A), PLGA (75:25) (B) and PLA (C).  
 
 
4.3.6. Drug release studies 
4.3.6.1. HPLC validation  
Prior to the release studies, a custom HPLC method was developed for the simultaneous 
monitoring of DOX and folic acid. The method required two mobile phases, (water with 
0.06 % TFA, and ACN with 0.06 % TFA), run on a gradient (Table 4.5); as folic acid is 
eluted first, the organic phase content is gradually increased to allow for the elution of 
DOX.  
A 
C 
B 
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Linearity, accuracy, precision, specificity and range are needed to validate a HPLC method. 
For this work the linearity was tested by using standard solutions to obtain calibration 
curves in the ranges of 0.05–2.00 and 5.00–100.00 µg/mL for folic acid and DOX 
respectively. Linear responses were observed for both concentration ranges tested, both 
having satisfactory correlation coefficient values (Figures 4.10 and 4.11).70   
 
 
Figure 4.10. Linearity curve for FA from mean standard curves with R2 values. 
 
 
Figure 4.11. Linearity curve for DOX from mean standard curves with R2 values. 
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The repeatability (intra-assay precision) was tested using 3 replicates over the same day. 
The intermediate precision, assessing variation within a laboratory, was calculated running 
samples over three separate days. The mean recovery, SD and % RSD were then 
analysed.71,72 Reproducibility considers inter-laboratory trials and was therefore not 
performed in this work.  
 
In Tables 4.13 and 4.14 the mean concentrations from recovery are close to the actual 
concentration values from the standard solutions with low SD values, suggesting that the 
HPLC method is acceptable for detection of folic acid and DOX.70 The % RSD for both 
folic acid and DOX are generally below 1.0 % (exception of the intermediate precision for 
folic acid 0.05 µg/mL), this indicates that there is good and acceptable repeatability for a 
HPLC method.70,72,73 The accuracy values are also acceptable for this method to be valid, 
as they need to be within 2.0 % of actual value, which they all are.70 
 
Table 4.13. Intra-assay precision (repeatability) and accuracy of five different standards 
run on HPLC. 
 
Compound 
Conc. 
(µg/mL) 
Recovery Accuracy 
(%) Mean concentration 
(µg/mL) (n = 3; ± SD) 
RSD (%) 
 
 
FA 
2.00 1.985 ± 0.014 0.702 99.25 
1.00 1.015 ± 0.009 0.870 101.50 
0.50 0.501 ± 0.040 0.881 100.20 
0.25 0.252 ± 0.015 0.686 100.80 
0.05 0.051 ± 0.000 0.380 102.00 
 
 
DOX 
100.00 99.53 ± 0.731 0.734 99.53 
50.00 49.69 ± 0.134 0.271 99.38 
25.00 24.76 ± 0.123 0.495 99.07 
10.00 9.984 ± 0.015 0.152 99.84 
5.00 5.047 ± 0.048 0.942 100.94 
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Table 4.14. Intermediate precision and accuracy of five different standards run on HPLC. 
 
Compound 
Conc. 
(µg/mL) 
Recovery Accuracy 
(%) Mean concentration 
(µg/mL) (n = 3; ± SD) 
RSD (%) 
 
 
FA 
2.00 2.001 ± 0.019 0.950 100.05 
1.00 1.011 ± 0.003 0.303 101.10 
0.50 0.504 ± 0.003 0.652 100.80 
0.25 0.250 ± 0.001 0.592 100.00 
0.05 0.051 ± 0.000 0.492 102.00 
 
 
DOX 
100.00 99.72 ± 0.572 0.574 99.72 
50.00 51.00 ± 0.028 0.055 102.00 
25.00 24.54 ± 0.034 0.140 98.19 
10.00 9.854± 0.009 0.091 98.54 
5.00 5.092 ± 0.047 0.932 101.84 
 
Specificity was tested by analysing a combined sample of folic acid and DOX and 
equations 4.1 – 4.3 were used to measure the validity of the method.  
 
As it can be seen from Figure 4.12, the folic acid and DOX peaks are completely separated, 
coming off at 2.223 and 8.885 minutes respectively. The tailing factors, as seen in Table 
4.15, show there is slight tailing but as the values are under 1.0 they are considered 
acceptable.74 The resolution is also over the required value of 1.5 that is considered 
acceptable according to the ICH.70  
 
 
Figure 4.12. HPLC chromatogram showing both FA and DOX peaks (detected at 254 nm 
wavelength).   
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Table 4.15. Peak details from the HPLC chromatogram (Figure 4.13).  
 FA DOX 
Retention time (minutes) 2.223 8.885 
Peak area 56.8 1009.0 
Theoretical plates 3186.6 5050.5 
Tailing factor  0.921 0.875 
Resolution 17.526 
 
The concentration ranges investigated for the validation studies were 0.05 – 2.00 and 5.00 
– 100.00 µg/mL for folic acid and DOX, respectively.  
 
The results obtained for the HPLC validation showed that the method was suitable to use 
for measuring both folic acid and DOX concentrations within the ranges employed for this 
work; the peaks were sufficiently separated and sharp enough to comply with the 
requirements of the ICH for HPLC method validation.  
 
4.3.6.2. Studies of drug release from electrosprayed nanoparticles loaded with DOX 
and folic acid 
Loaded nanoparticles were incubated in microcentrifuge tubes placed into a water bath at 
37 °C; the tubes were sequentially removed at pre-determined time points and centrifuged, 
the supernatant was removed and measured using a validated HPLC method (described in 
chapter 4.3.6.1) that allowed the determination of both DOX and folic acid concentration. 
 
A typical burst release of DOX was observed within the first day from all three types of 
polymeric nanoparticles (a release of 54.3, 57.4 and 44.5 % for PLGA 50:50, 75:25 and 
PLA respectively, over 10 h), with a slow release stage following and with the PLGA 
(50:50) based nanoparticles releasing most of the drug over one week (Figure 4.13). This 
appears typical for DOX release from PLGA nanoparticles.75,76  
 
It was found that DOX would take more than one week to be released completely; the 
slowest release was observed from PLGA (75:25), with 78.9 % drug released over 1 week. 
As expected, folic acid was released faster than DOX, for all types of polymer 
nanoparticles (Figure 4.14). In contrast to DOX, within a day nearly all folic acid had been 
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released (release after 10 h was 98.9, 88.6 and 84.6 % for PLGA (50:50), (75:25) and PLA 
respectively). 
 
 
Figure 4.13. Release profiles of DOX from electrosprayed nanoparticles containing DOX 
and FA (n = 5; ± SD).  
 
 
 
Figure 4.14. Release profiles of FA from electrosprayed nanoparticles containing DOX 
and FA (n = 5; ± SD). 
 
 
For PLGA (50:50) nanoparticles (Figure 4.15), almost all folic acid was released after 
approximately 10 h, suggesting folic acid was distributed on, or close to the surface of the 
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particles (or it dissolved in PBS as soon as the particles began to degrade). The same 
differences can be seen in the release profiles of folic acid from both the PLGA (75:25) 
and PLA particles (Figures 4.16 and 4.17 respectively), however the release of folic acid 
from PLGA (75:25) particles was not complete over the period of the experiment, yet the 
amount released reached its maximum at 24 hours. The PLA particles release the majority 
of the folic acid within the first 10 hours, however there was still a slow release of folic 
acid between 10 hours all the way up to one week. This could be due to PLA breaking 
down slower in PBS (compared to the PLGA (50:50) and (75:25)) and perhaps to the fact 
that the folic acid incorporated more within the polymeric particles and not just on the 
surface. The PLA particles were loaded with nearly double the amount of folic acid, which 
also could have had an effect on the release profiles.  
 
 
 
Figure 4.15. Release profiles of DOX and FA from electrosprayed PLGA (50:50) 
nanoparticles containing DOX and FA (A), with zoom in on the first 24 h of release (B)    
(n = 5; ± SD). 
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Figure 4.16. Release profiles of DOX and FA from electrosprayed PLGA (75:25) 
nanoparticles containing DOX and FA (A), with zoom in on the first 24 h of release (B)    
(n = 5; ± SD). 
 
 
 
Figure 4.17. Release profiles of DOX and FA from electrosprayed PLA nanoparticles 
containing DOX and FA (A), with zoom in on the first 24 h of release (B) (n = 5; ± SD). 
A	  
B 
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It is therefore likely that the initial release is due to the DOX present on, or close to the 
surface of the polymer matrix; in the slower release stage, the process starts being 
controlled by the degradation of the polymer, gradually allowing the DOX present within 
the polymeric matrix to come into contact with PBS and allowing diffusion to occur. 
Similar phenomena have been previously reported for PLGA particles prepared by solvent-
evaporation, where the release of drugs occurs initially by diffusion from the polymer 
matrix, while in the later stages the release is controlled by both diffusion and degradation 
of the polymer matrix; the diffusion of the aqueous phase into the particles causes the 
polymer chains to degrade, leading in turn to an enhanced diffusion of the entrapped 
drug.77  
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4.4. Conclusions 
Preparation of dual-loaded nanoparticles using a one-step electrospraying process was 
successfully carried out, with particle diameters ranging between 90 and 106 nm. Both a 
chemotherapeutic drug (DOX) and a targeting agent (folic acid) were loaded 
simultaneously, with the aim of improving the cytotoxic effect of DOX while limiting the 
side effects. The change in zeta potential values for nanoparticles loaded with both DOX 
and folic acid (compared to just DOX) suggests that folic acid is likely present on the 
surface of the nanoparticles.   
 
The nanoparticle diameter was found to generally decrease with increasing collection 
distance, with an optimum around 15 cm, above which the particle size can sometimes 
increase likely due to jet instability. This trend was seen for all three types of polymeric 
nanoparticles (50:50, 75:25 and PLA), which would suggest this could possibly apply to 
other polymers as well.  
 
The results of the optimisation experiments on the loading of DOX also indicated that the 
particle size only slightly decreases with an increase in the concentration of DOX solution 
subjected to electrospraying (from 0.2 to 0.5 % w/v), no significance shown by t-test.  
 
The electrosprayed dual-loaded (folic acid and DOX) nanoparticles were found to be stable 
after freeze-drying and re-dispersion in PBS, with no significant change in particle 
diameter or PDI values, and were prepared in sufficient amount to be used further for in 
vitro cytotoxicity and cellular uptake experiments.  
 
FTIR results confirmed successful loading of DOX while the low content of folic acid 
within the nanoparticles could not be detected using this technique. However, its 
concentration could be conveniently measured using a specifically developed HPLC 
gradient method that was successfully validated for the concurrent analysis of both DOX 
and folic acid present in the same sample.  
 
Release profiles of DOX and folic acid from these nanoparticles showed that the folic acid 
was almost completely released within 10 hours from all three types of nanoparticles, 
suggesting that it could be located in majority on the surface of the nanoparticles.  This is 
not necessarily considered a disadvantage for targeting the folate receptors as folic acid has 	  	   113	  
been found in vivo to be taken-up into tumours within 3 hours.78 There was an initial burst 
release of DOX over the first 24 h and then the release plateaued, with the complete release 
requiring over one week; in accordance to literature, the release of DOX is likely to occur 
via a combination mechanism involving relatively concomitant diffusion and degradation 
of the polymer matrix.  
 
EHDA was therefore found as a suitable and extremely easy one-step method to prepare 
PLA and PLGA nanoparticles loaded with both DOX and folic acid, as proven by FTIR, 
HPLC, zeta potential and particle diameter data. While results evidenced a fast release of 
folic acid from PLA and PLGA nanoparticles, this might be long enough to allow folic 
acid to play its tumour targeting role while circumventing the current disadvantages of 
most alternative methods of incorporating folic acid into particulate drug carriers (such as 
conjugation, emulsification, coagulation and dialysis).79,80–83  
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5. In vitro evaluation of folic acid-functionalised 
PLA/PLGA nanoparticles for the targeted treatment of 
lung cancer 
 
5.1. Introduction 
The results presented in this chapter focus on investigating the targeting properties of folic 
acid-functionalised PLA/PLGA nanoparticles loaded with doxorubicin as an anticancer 
agent (optimised as described in Chapter 4). Studies using both human lung cancer cells 
and normal bronchial cell lines involved cytotoxicity measurements by means of MTT 
assays and cellular uptake investigations employing confocal microscopy, live cell imaging 
and flow cytometry.   
 
5.1.1. Tumour cells - generalities 
Cancer is generally defined as any malignant tumour (including carcinoma, lymphoma, 
leukaemia and sarcoma) that arises from the abnormal, purposeless, and uncontrolled 
division of cells that invade and destroy the surrounding tissues.1 Tumours develop 
through genetic alterations of normal cells, which in turn affect the growth control systems 
leading to abnormal cell growth.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. The six hallmarks of cancer (reproduced from 2). 	  	   123	  
The six hallmarks of cancer that a cell must acquire before it becomes one of many 
different types of human malignancies have been identified2 (Figure 5.1), as follows:  
1. Sustaining proliferative signalling and the ability of cancer cells to sustain chronic 
proliferation: normal cells control the production and release of growth-promoting 
signals, allowing entry and progression through the growth and division cycle, but 
cancer cells deregulate these signals enabling them to bypass growth factor 
pathways and grow unregulated.  
2. Evading growth suppressors: cancer cells become insensitive to the normal anti-
growth signals, which normal cells respond to preventing them from dividing 
randomly, mutations within cancerous cells leave these signals to be 
unrecognisable.  
3. Activating invasion and metastasis: cancer cells can develop the ability to migrate, 
allowing them to become invasive and metastasise, once this happens it makes the 
cancer difficult to treat.  
4. Enabling replicative immortality: normal cells can only pass through a certain 
number of growth-and-division cycles, cancer cells require an unlimited replicative 
potential.  
5. Inducing angiogenesis: an ‘angiogenic switch’ is constantly turned on in tumour 
cells allowing them to require sustenance and evacuate metabolic waste products, a 
need of tumour cells like normal tissues.  
6. Resisting cell death: normal cells that acquire mutations will undergo apoptosis 
however cancer cells employ strategies to avoid apoptotic pathways.   
 
5.1.2. Lung cancer 
In 2011 lung cancer was the second most common cancer in the UK with over 43,000 
people being diagnosed, and in 2012 there were over 35,000 deaths from lung cancer. For 
adult lung cancer patients diagnosed between 2010 and 2011 in England and Wales, only 
5 % were predicted to survive more than ten years. Major lifestyle factors along with other 
risk elements make up 89 % of lung cancer cases within the UK each year.3 The amount of 
diagnosed cases of lung cancer in men has decreased over the past four decades (Figure 
5.2) and this is believed to be connected to the increase in knowledge of the dangers of 
smoking to health. 
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Figure 5.2. Lung cancer incidence rates (per 100,000 people) in UK between 1993 – 2011 
(from 4).  
 
The human lungs (Figure 5.4) are essential respiration organs whose main function is to 
transport oxygen into the bloodstream and remove carbon dioxide. The lungs have a very 
large surface area, required for the exchange of gases. They are a pair of cone-shaped 
organs that are located within the thoracic cavity, almost filling the thorax.  
 
Figure 5.3. Diagram of the human lungs, branching down from the trachea (adapted from 
5).   	  	   125	  
Each lung is protected by a double-layered serous membrane called the pleural membrane. 
The lungs extend from the diaphragm to slightly superior of the clavicles and lie against 
the ribs (anteriorly and posteriorly). The left lung contains a concavity (known as the 
cardiac notch) where the heart lies, meaning that the left lung is approximately 10 % 
smaller than the right lung.5 A more detailed diagram of the lungs can be seen in Figure 5.4, 
showing how the trachea branches off to the primary bronchi (then secondary and tertiary) 
and onto the bronchioles, which subdivide further into the alveolar ducts.   
 
Figure 5.4. Diagram of a portion of the lobule of the lung (adapted from 5).  
 
There are various types of lung cancer, the main two categories being small cell lung 
cancer and non-small cell lung cancer (NSCLC), as detailed in Table 5.1. 
 
Three risk factors that are associated to lung cancer are diet (lack of fruit and vegetables), 
occupation and, most importantly, smoking.6 The risk of death from lung cancer is 
approximately 15 times higher for current smokers (compared with those who have never 
smoked), as shown in an all-male study.7 The risk increases with both the duration and the 
amount that the patient has smoked, however the duration is believed to have a larger 
effect.8,9  	  	   126	  
Table 5.1. Types of primary lung cancer. 
Name (Type) Description  
 
Small cell lung cancer 
Makes up approximately 12 % of lung cancers and is 
named due to the cells looking small under the microscope. 
Smoking usually causes this cancer. 
 
 
Non-
small cell 
lung 
cancer 
 
Squamous 
cell cancer 
This is the most common type of primary lung cancer. It is 
often found in the centre of the lung (main airways) and 
develops from the cells that line the airways. Smoking often 
causes this type of cancer.  
 
Adenocarcinoma 
This is produced from a particular cell along the airway that 
produces mucus and is often found within the outer areas of 
the lungs. There are many sub types of adenocarcinoma.  
Large cell 
carcinoma 
The cells look rounded and large under the microscope and 
this type of lung cancer grows quickly.  
 
Mesothelioma 
A rare type of lung cancer that affects the pleura of the lung 
(covering). It is very different to other types of lung cancer 
and is often caused by exposure to asbestos.  
 
 
5.1.2.1. Current treatments of lung cancer 
There are various methods for the treatment of lung cancer, ranging from those commonly 
used such as surgery and chemotherapy to more innovative methods such as photodynamic 
therapy. 
 
Surgery 
Treatment for lung cancer depends on the type of cancer (non-small cell or small cell); for 
non-small cell lung cancer the most common treatment is surgery (when the cancer is 
confined to one lung) followed by a course of chemotherapy used to destroy any cancer 
cells remaining. The most common treatment for small cell lung cancer is chemotherapy 
(alone or combined with radiotherapy); surgery is not common for this type of cancer due 
to the patient usually being diagnosed after the cancer has already spread to other areas 
within the body.10 Different types of surgery for lung cancer are outlined in Table 5.2. 
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Table 5.2. Main types of surgery for lung cancer.   
Name of Surgery Definition 
Lobectomy One or more lobes of the lung are removed – for when the 
cancer is located within one section of a single lung.  
Pneumonectomy Entire lung is removed – for when cancer is either located 
within the middle of a lung or has spread throughout a lung.  
Wedge resection/ 
Segmentectomy 
Small piece of a lung is removed - not very common and for 
when the cancer is small and limited to one area with a lung 
(early stage non-small cell lung cancer). 
 
Radiotherapy 
Often radiotherapy is combined with chemotherapy for small cell lung cancer when it is in 
its early stages. When radiotherapy is given after chemotherapy, this is known as 
sequential treatment, while when both radiotherapy and chemotherapy are given together 
the treatment is known as concomitant chemo-radiation.11 
 
Alternative treatment methods 
Table 5.3. Less common methods of treatments for lung cancer.   
Treatment Name Treatment Details Lung cancer type 
 
Biological 
therapy 
Treatments that control or stop 
the growth of cancer cells. 
Mainly for advanced non-small cell lung 
cancer but some new drugs for biological 
therapy are in clinical trials for earlier 
stages of lung cancer. 
 
Radiofrequency 
ablation 
This type of treatment uses 
radio waves to kill cancer 
cells, the electrical energy 
heats up the tumour, killing 
the cancer cells.  
Normally for the treatment of early stage 
non-small cell lung cancer or advanced 
lung cancer.   
 
Photodynamic 
therapy 
A photosensitising drug is 
combined with a laser light to 
destroy cancer cells.  
Early stage non-small cell lung cancer or 
advanced lung cancer (where the tumour 
is blocking the airway). 
 
Cryotherapy 
The cells are frozen to kill 
them, shrinking tumours that 
are blocking the airway.  
Advanced lung cancer. 
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There are a few other methods for treating lung cancer which are less commonly used due 
to them being more specialised towards certain types of lung cancer, as detailed in Table 
5.3.12–15 
 
5.1.2.2. Chemotherapy 
Cytotoxic drugs are used to destroy cancer cells by damaging them to the extent that they 
cannot reproduce or spread and represents the main treatment for small cell lung tumours. 
Small cell lung cancer responds extremely well to chemotherapy,16 that is normally 
administered intravenously and can be used for various reasons: as a cure alone, to make 
other treatments more effective, to reduce the risk of cancer returning or to relieve the 
symptoms. Doxorubicin, cisplatin or paclitaxel are just a few of the many examples of 
chemotherapy drugs currently in use and that can be administered alone or in combination 
(Table 5.4), now a recognised way of treating lung cancer (especially for recurrent lung 
cancer).16 Non-small cell lung cancer is usually treated with surgery followed by 
chemotherapy, and combination chemotherapy has been proven to be the most effective. 
 
Table 5.4. Common combination chemotherapies for the treatment of lung cancer.  
Chemotherapy 
combination  
Drugs 
included 
Indication 
EP Cisplatin 
Etoposide 
 
Small cell  
lung cancer 
Carbo 
etoposide 
Carboplatin 
Etoposide 
GemCarbo Gemcitabine 
Carboplatin 
 
ACE 
Doxorubicin 
Cyclophosphamide 
Etoposide 
 
 
 
Cancer 
recurrence 
 
CAV 
Cyclophosphamide 
Doxorubicin 
Vincristine 
 
CAVE 
Cyclophosphamide 
Doxorubicin 
Vincristine 
Etoposide 
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5.1.3. Targeting cancer cells  
A major disadvantage that comes with current treatment approaches such as radiotherapy 
or chemotherapy is that they can damage normal cells as well as cancer cells, and the 
selectivity of these treatments is one of their main current limitations. Traditional 
chemotherapy drugs act against all cells that are actively dividing, therefore specific and 
selective targeting of tumour cells has become lately one of the main goals of current 
research; this would allow a higher drug level within the tumour tissue compared with 
normal tissue, and minimal side effects.  
 
In the case of drug carrier formulations, nanoparticles need to be functionalised with 
certain molecules that can recognise specific biomarkers on the surface of the tumour cells. 
These targeted cancer therapies could act on specific molecular targets associated with 
cancer growth, progression or spread,17 acting therefore as cytostatics and by blocking cell 
proliferation.  
 
Opsonisation  
In vitro studies have shown that the charge on nanoparticles correlates with the chances of 
opsonisation occurring; a neutral charge resulting in a lower opsonisation rate compared to 
nanoparticles with a surface charge.18 This can be utilised as a method for targeting 
nanoparticles as a cell or receptor specific controlled delivery system and has been used for 
delivery to the central nervous system.19,20  	  
Protein corona effects Once	  nanoparticles	  come	  into	  contact	  with	  bodily	  fluids,	  proteins	  surround	  them,21,22	  which	   then	   determines	   the	   physicochemical	   properties	   of	   those	   nanoparticles	  (surface	   charge,	   aggregation	   behaviour,	   cellular	   uptake	   mechanism	   and	  hydrodynamic	   size).23–25	   As	   the	   proteins	   surround	   the	   nanoparticles	   they	   have	   the	  primary	   contact	   with	   the	   cells26,27	   and	   therefore	   the	   protein	   corona	   defines	   the	  biological	   identity	  of	   the	  nanoparticle	   that	  will	   impact	  upon	  the	  distribution	  around	  the	  body,	  cytotoxicity	  and	  endocytosis.	  	  Protein	   corona	   formation	   can	   be	   limited	   by	   modification	   of	   nanoparticles,	   with	  research	  showing	  that	  the	  addition	  of	  polyethylene	  glycol	  to	  nanoparticles	  can	  reduce	  	  	   130	  
cellular	  uptake	  possibly	  due	  to	  it	  reducing	  the	  adsorption	  of	  proteins.28	  Nanoparticles	  that	  are	  zwitterionic	  have	  been	  shown	  to	  lack	  a	  protein	  corona.29	  	  
 
5.1.4. Specific targeting for lung cancer 
Currently there two main types of targeted therapies specific for the treatment of lung 
cancer, namely monoclonal antibodies (Bevacizumab) and cancer growth inhibitors 
(Erlotinib and Gefitinib), Table 5.5. They are normally used for the treatment of non-small 
cell lung cancer and act by targeting and blocking key factors required by the cancer cells.  
 
Table 5.5. Specific targeted treatments for lung cancer.30 
Name of targeted 
therapy (drug) 
Targets Details Lung 
cancer type 
Avastin 
(Bevacizumab) 
Protein – vascular 
endothelial 
growth factor 
Targets a protein that helps cancer 
cells develop a new blood supply 
(angiogenesis inhibitor). 
 
NSCLC 
Tarceva (Erlotinib) 
+ 
Iressa (Gefitinib) 
 
Kinase proteins 
Blocks/inhibits signals within cancer 
cells that allow them to grow and 
divide (tyrosine kinase inhibitor). 
 
NSCLC 
 
 
5.1.5. Overview of the main techniques employed in vitro  
In vitro studies involve cells or biological molecules outside their normal biological 
context, namely cells are grown in culture medium or proteins are examined in solutions. 
Testing cells separate from their normal biological environment is a well proven, reliable 
and very convenient way to preliminary test important characteristics of drug delivery 
systems such as their cytotoxicity, cellular uptake or membrane crossing ability.  
 
While animal models can be very complicated for initial/basic research (still without 
managing to always mimic the human body)31, in vitro models are simpler and easier to 
study and can provide critical preliminary information. The cell lines employed in this 
work were lung cell lines: CALU-3 and 16HBE cells.  
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5.1.6.	  Lung	  cell	  lines	  	  
	  
CALU-3 cells  
A principal cell line commonly used as an in vitro model of respiratory epithelium32,33 due 
to its ability to form tight monolayers when in culture, CALU-3 cells can express the cystic 
fibrosis transmembrane conductance regulator protein34,35 and is also known to 
overexpress folate receptors.36 
 
16HBE cells 
This cell line retains differentiated epithelial morphology and functions and also expresses 
levels of both cystic fibrosis transmembrane conductance regulator mRNA and protein,37,38 
which makes it a good cell line to be used as control against CALU-3 cells. 16HBE cells 
do not overexpress folate receptors.39,40  
 
Important characteristics considered when testing nanoparticulate drug formulations 
include cytotoxicity and cellular uptake. To measure cytotoxicity (sometimes expressed as 
cell viability), assays monitor various functions of cells including: enzyme activity; cell 
membrane permeability; cell adherence; ATP production; co-enzyme production; or 
nucleotide uptake. Most assays rely on colorimetric measurements and the ones employed 
in the work presented here will be discussed in more detail in section 5.1.7. Cellular uptake 
can be investigated qualitatively using various imaging techniques (confocal microscopy 
or live cell imaging) or quantitatively (by using fluorescent markers and techniques such as 
flow cytometry). 
 
5.1.7. Cytotoxicity assays 
MTT is one of the most widely used assays for testing cytotoxicity; it is a colorimetric 
assay and determines toxicity by measuring the colour change from a yellow tetrazole (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) to the insoluble 
formazan form (purple) within the living cells, specifically in the mitochondria (however 
there was no evidence to suggest the MTT reaction was confined to the mitochondria).41 
The insoluble formazan crystals have to be solubilised with DMSO before readings can be 
taken, and the signal generated is dependent on the degree of activation of the cells 
therefore it can be used to detect cytotoxicity, proliferation or activation.42 MTT assays are 
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not adequately sensitive at low cell numbers and therefore a calibration curve should be 
run first to ensure the cell numbers are within a suitable range.43,44 
 
There are other assays for determining cell death that use dyes such as trypan blue or 
propidium iodide, compounds that are normally excluded from healthy cells but the leaky 
membrane of dying/dead cells allows them to be easily uptaken.45 However to quantify one 
would have to use a microscope to count the stained cells, therefore these methods are not 
as easy or accurate compared to the MTT assay. Lactate dehydrogenase (LDH) assay also 
determines cell death by measuring the neuronal apoptosis; the loss of intracellular LDH 
and the release into culture medium indicates irreversible cell death by damage to the 
cellular membrane.46 Research by Fotakis et al.46 showed that the MTT assay was more 
sensitive than the LDH assay. A downside to MTT assays is the fact that the formazan 
crystals damage the cells, which therefore cannot be re-used.  
 
5.1.8. Confocal microscopy 
Confocal microscopy is an optical imaging technique that has an advantage over other 
conventional optical microscopes because of its ability to eliminate out-of-focus glare, to 
collect serial optical sections from thick specimens, and to allow for shallow depth of 
field.47 A major application of confocal microscopy imaging involves live/fixed cells and 
tissues that can be labelled with fluorescent probes. A simple set up of a confocal 
microscope is presented in Figure 5.5.  
 
Figure 5.5. Schematic representation of a typical confocal microscope (from 48). 
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5.1.9. Live cell imaging 
Live cell imaging allows cells to be monitored in real time by using an inverted 
microscope equipped with a special specimen chamber (Figure 5.6).   
 
 
 
 
Figure 5.6. Generalised set up of live cell imaging microscope (adapted from 49). 
The compartment maintains a controlled environment that can be adjusted to the needs of 
the sample (to ensure the cells stay alive). Experiments are normally run in 24 well plates 
and set time intervals can be selected for imaging. The microscope has a fluorescence 
detector allowing for the fluorescence probes to be tracked over time.49,50 
 
5.1.10. Flow cytometry 
Flow cytometry is a technique that senses cells or particles when they are moving within a 
liquid stream through a laser and past a sensor where the relative light scattering and 
fluorescence are measured (schematic seen in Figure 5.7). If a fluorescent marker was 
attached to, or incorporated into nanoparticles, the fluorescence will be sensed when the 
cells pass in front of the detector.51 Flow cytometers have several lasers that can measure 
at different excitation wavelengths; scattered and emitted fluorescent light is collected by 
two lenses, one which is set in front of the light source (forward scatter) and another set at 
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right angles (side scatter); through a series of optics, beam splitters and filters, specific 
bands of fluorescence can be measured. Flow cytometry is therefore able to measure 
physical characteristics including cell size, shape and internal complexity, along with any 
cell component or function that can be made detectable by conjugation with a fluorescent 
compound.52  
 
 
Figure 5.7. Schematic representation of a typical flow cytometer with 4 lasers (from 52).   
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5.2. Experimental details 
 
5.2.1. Materials 
Dulbecco’s modified eagle’s medium (DMEM), minimum essential medium (MEM), 
Tryple Express and phosphate buffered saline (PBS) were purchased from Invitrogen, Life 
Technologies (Loughborough, UK). The Hoechst blue 33342 was purchased from Gibco, 
Life Technologies (Loughborough, UK). Triton X–100 (T-X), DMSO (cell culture grade), 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Trypan blue, fetal 
bovine serum (FBS), penicillin streptomycin and the 96, 24 and 6 well plates (Greiner bio-
one) were purchased from Sigma Aldrich (Dorset, UK). The 25 and 75 cm2 Corning 
culturing flasks were sourced from Fisher Scientific (Loughborough, UK).   
 
5.2.2. Cell cultures  
The composition of media the CALU-3 cells were grown in was DMEM modified with 
FBS (10 %), Penicillin/Streptomycin (1 %) and non-essential amino acids (1 %). The 
composition of media the 16HBE cells were grown in was MEM modified with FBS 
(10 %), L-Glutamine (1 %) and anti-mycotic and antibiotic (1 %). The cells were cultured 
under a humidified atmosphere maintained at 37 °C with 5 % CO2 in a Nuaire DH 
Autoflow Air-Jacketed incubator (Plymouth, USA). The cells were observed on a Zeiss 
(Axiovert 40C) microscope (Thornwood, USA). The CALU-3 cells were used between 
passages 26 – 38 and the 16HBE cells between passages 30 – 38.  
 
Cell passaging 
Cells were split every few days when they became 80 – 90 % confluent, as follows: 
DMEM removed, cells washed thrice with PBS, trypsinised with Tryple Express (1 mL per 
flask, incubated for 10 minutes at 37 °C until cells became detached), DMEM was added, 
which deactivated the Tryple Express still present, and then split out into fresh culture 
flasks (6 mL per flask).   
 
Cell counting 
Cell suspensions were centrifuged with a Boeco C-28 centrifuge (Hamburg, Germany) and 
cells were counted with a glass haemocytometer. After trypsinisation of the cells DMEM 
was added to deactivate the Tryple Express and the cell suspension was centrifuged (1500 
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rpm; 1046 g; 3 min), the supernatant discarded. The cell pellet was re-suspended in 
DMEM (1 mL) and then the cells were counted using a haemocytometer.   
 
Cyropreservation and resurrection of cells 
Cells were treated as in the cell passaging section in order to detach them and then were 
centrifuged (1500 rpm; 1046 g; 3 min) before being re-suspended in 1.0 mL of recovery 
medium (supplemented with 10 % DMSO) in a cryotube. This was frozen at -80 °C 
overnight then submerged in a tank of liquid nitrogen for storage.  
 
For cell resurrection, cryotubes were taken from the liquid nitrogen tank, placed into a 
plastic box for 2 minutes then transferred into an incubator (37 °C) to thaw the cell 
suspension. The content of the cyrotube was then transferred into a flask with 6 mL of 
modified media at 37 °C. The flask was maintained in an incubator for 24 h, the media was 
removed and centrifuged (18,000 rpm; 21,350 g; 3 min) to collect any cells that had not 
attached to the flask. The pellet was then re-suspended in 6 mL modified media and added 
back into the flask, ensuring that the DMSO within the freezing medium had been removed.    
 
Cell seeding density 
The cell seeding density was investigated first to ensure that the density used for the MTT 
assay was within a linear range (Figures 5.8 to 5.10). A cell seeding density of 10,000 cells 
per well was therefore used further for the MTT assay for both 16HBE and CALU-3 cell 
lines. 
  
Figure 5.8. Calibration curve for 16HBE cells (n = 12).  
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Figure 5.9. Calibration curve for CALU-3 cells (n = 12).   
 
 
 
Figure 5.10. Zoom in of CALU-3 calibration curve to check linearity (n = 12).  
 
 
5.2.3. Cytotoxicity assay 
MTT in DMEM (5 mg/mL) was incubated at 37 °C, then diluted (1:4) with DMEM, which 
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???? ????????????????? ???????? ????? ??? ?????????? ???? ?????????????? ???? ???????????of 
nanoparticles in PBS ?????????????????????????????????????????????????????? (4, 8 and 24 h), 
the medium was tipped off and a working solution of MTT (prepared as above) was added 
???????????????????????The plate was incubated in the dark at 37 °C (1 h). The medium was 
then tipped out and DMS???????????? ????????????????????????late was shaken for few 
minutes to break up the crystals formed from the MTT, and absorbance from the 96 well 
plate was measured with a PolarStar Optima plate reader (BMG Labtech, 
Buckinghamshire, UK) at 570 nm. Experiments were run on three separate days at 
different passage numbers (CALU-3: 28 – 33; 16HBE: 33, 35 and 37).  
 
Table 5.6. The weight ??? ??????????????????????????????? of varying concentrations. 
 
The concentrations of DOX used in literature against cancer cells generally range from 0.1 
– ??????????????– ???????/mL),53–56 the amounts used in this work can be seen in Table 
5.6 and are similar to the lower range of these concentrations.   
 
5.2.4. Statistical analysis 
The statistical analysis was performed using IBM SPSS statistics 22 software (Armonk, 
New York); the results were checked for normal distribution using normality plots then the 
statistical significance was tested using one-way analysis of variance (ANOVA) followed 
by post hoc Tukey test (p values set at 0.05), as detailed in Chapter 3. 
 
5.2.5. Flow cytometry 
Samples were prepared in 6 well plates with cells seeded at 105 cells per well and left for 
24 hours to settle. Nanoparticle treatments (10 mg/mL of nanoparticles - ?????????????? 
in modified media (as stated in section 5.2.2) were added to each well and left to incubate 
for 24 hours. After the incubation period the nanoparticles and media were removed and 
the cells were washed three times with PBS. The cells were then centrifuged (18,000 rpm; 
Nanoparticle 
concentration 
1 mg/mL 
???/mL) 
3 mg/mL 
???/mL) 
6 mg/mL 
???/mL) 
10 mg/mL 
???/mL) 
PLGA (50:50) 48.9 146.7 293.4 489.0 
PLGA (75:25) 55.8 167.4 334.8 558.0 
PLA 47.2 141.6 283.2 472.0 
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21,350 g; 3 min), the supernatant disposed of and the cells re-suspended in PBS. Samples 
were analysed with a BD FACS Calibur - fluorescence activated cell sorter (Oxford, UK) 
using the FL2 channel (585/42 nm). Experiments were run on three separate days at 
different passage numbers (CALU-3: 34, 35 and 37; 16HBE: 34, 36 and 38). 
 
5.2.6. Confocal and fluorescence microscopy studies 
CALU-3 cells were seeded onto square glass cover slips (1 x 105 cells) in 6 well plates and 
incubated in 2.0 mL of modified DMEM for 24 hours at 37 °C. The media was then 
replaced with 2.0 mL of nanoformulation (2 mg of nanoparticles loaded with DOX base 
and FA) and left to incubate for 3 hours at 37 °C. After incubation the media was discarded 
and the cells were washed thrice with PBS. They were then fixed with paraformaldehyde 
(4.0 % w/v) for 20 min at 4 °C, permeabilised with Triton X-100 (0.1 % v/v) for 20 mins at 
room temperature and then incubated with nuclear counter-stain Hoechst 33342 (5.0 
??????? ???? ??? ???? ??? ????? ????????????? ?????? ?????? ????? ?????? ??? ??????????? ???????
(mounting medium included to ensure cells did not dry out) and then observed under a 
LSM 710, ZEISS confocal microscope (Herts, UK), using wavelength 405 nm for Hoechst 
and 543 nm for DOX.  
 
5.2.7. Live cell imaging 
Samples were prepared in a 24 well plate; cells were seeded at 5 x 103 per well and left to 
settle for 24 h in modified media, which was then removed and replaced with nanoparticles 
dispersed in modified media (3 mg/mL). Samples were then monitored by live cell 
imaging using a Zeiss Axiovert 200M (inverted) microscope (Carl Zeiss, Herts, UK) 
equipped with an incubator (37 °C, 5 % CO2, humid atmosphere). A 40X objective was 
used, and bright field and fluorescence (filter set no. 20 ‘Rhodamine’, excitation 546/12 
nm, emission 575 – 640 nm; Zeiss) images were consecutively acquired every 15 min for 
24 h (V5.4, Perkin Elmer). Images were processed using Volocity software (V6.1.1, Perkin 
Elmer). 
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5.3. Results and discussion  
All types of nanoparticles (PLGA (50:50), PLGA (75:25) and PLA), loaded with both 
DOX and folic acid (prepared and characterised as presented in chapter 4), were 
investigated for their interactions with human lung cell lines. Nanoparticles loaded with 
DOX alone were employed as controls to assess the targeting effect of the folic acid. 
Cytotoxicity and cellular uptake of nanoparticles were studied using cell viability assays, 
flow cytometry, confocal microscopy and live cell imaging.  	  
5.3.1. Cytotoxicity studies 
The loaded nanoparticles were tested on both cancer and normal human lung cell lines. 
The action of folic acid as a targeting agent was also investigated; the lung epithelial cell 
line CALU-3 was selected for this study as these cells are known to overexpress folate 
receptors.36  
 
5.3.1.1. Cytotoxicity effect of the individual components 
Results of MTT assays showed that there were no significant differences between the 
viability of cells treated with any of the electrosprayed unloaded polymeric nanoparticles 
and that of cells treated only with PBS (used as control), even at concentrations as high as 
10 mg/mL (in the case of PLGA (50:50)), Figure 5.11. This indicates that the unloaded 
polymeric nanoparticles do not have any intrinsic cytotoxic effect on the cells tested. Also, 
folic acid alone does not have a significant toxic effect (p value = 1.000) on the CALU-3 
cells (Figure 5.12). 
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Figure 5.11. Cytotoxicity of unloaded electrosprayed nanoparticles (PLA or PLGA 
nanoparticles alone) on CALU-3 cells (24 h incubation), with PBS as negative control (n = 
6; ± SD). 
 
Incubation with electrosprayed PLA/PLGA nanoparticles (loaded with free doxorubicin 
base) does affect the cells (Figure 5.12; NPs + D), however there is no significant 
difference compared to the PBS results (p value = 0.957) and therefore the decrease in cell 
viability is possibly due to the shock of having the nanoparticles added (Figure 5.12).  
 
 
Figure 5.12. Cytotoxicity results following incubation of CALU3 cells with: FA alone (3 
mg/mL); (PLGA (50:50)?? ?????????????? ??? ??????? ??????? ????? ???? ??????? ??/mL of 
DOX), free DOX base (concentrations corresponding to the concentrations given in Table 
5.6) and Triton-X 100 (T-X); 24 h incubation time (n = 6; ± SD). 
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When loaded with free DOX base, nanoparticles did have a significant effect on the 
viability of CALU-3 cells (significant difference compared to the PBS control; p value = 
0.000 for all 4 concentrations tested). The difference was however slightly higher for 
nanoparticles loaded with DOX salt (Figure 5.13) perhaps due to the fact that DOX base 
has a very limited solubility in PBS.57 The increased solubility of DOX salt in water 
suggests that it can be used as a model of hydrophilic drugs and the DOX base a model of 
lipophilic drugs.57 Both free DOX base and DOX salt had an effect on the viability of the 
cells, and the difference when compared to the cells incubated with PBS was significant, p 
value (ANOVA) for all was 0.000 (Figure 5.13). 
 
 
Figure 5.13. Cytotoxicity of DOX (free base and salt forms) on CALU-3 cells (n = 6; ± SD).   
 
In summary, the unloaded nanoparticles (tested in concentration up to 10 mg/mL) do not 
decrease the CALU-3 cells viability and neither does folic acid alone (tested in 
concentration of 3 mg/mL); the only significant cytotoxic effects observed were due to the 
DOX loaded into the nanoparticles (in both salt and free base forms) and were, as expected, 
concentration dependent. 
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5.3.1.2. Cytotoxicity of DOX- and folic acid-loaded nanoparticles 
Dose response experiments were carried out by measuring CALU-3 cells viability 
following incubation with different types of polymeric nanoparticles (loaded with both 
DOX and FA), at concentrations of 1, 3, 6 and 10 mg/mL; as expected, the cell viability 
decreased with increasing nanoparticle concentration (Figure 5.14).  
 
 
Figure 5.14. Cytotoxicity results following incubation for 24 h of CALU-3 cells with 
electrosprayed nanoparticles loaded with both DOX base and FA (n = 6; ± SD).  
 
 
To test the effect of cell passage number on the response observed in the cell viability tests, 
experiments were repeated on different days with different passage number cells; data 
from each day is presented in Table 5.7, where it can be seen that the results do not vary 
significantly on each different run, suggesting that they are not dependent on the cell 
passage number (p values all less than 0.05). 
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Table 5.7. Individual inter day data of cytotoxicity studies (dose response) on CALU-3 
cells incubated for 24 h with electrosprayed PLA/PLGA nanoparticles dual drug loaded 
with both DOX base and FA (n = 6; ± SD). 
Polymer Concentration 
(mg/mL) 
Cell viability against PBS (%) [passage number] 
Day 1 
[28] 
Day 2 
[29] 
Day 3 
[31] 
Mean 
 
 
 
PLGA 
(50:50) 
10 47.9 
± 2.3 
50.7 
± 2.1 
47.8 
± 1.9 
48.0 
± 1.7 
6 48.8 
± 3.7 
55.8 
± 2.2 
52.2 
± 4.1 
52.3 
± 3.5 
3 67.9 
± 1.9 
59.7 
± 2.1 
62.8 
± 3.2 
63.5 
± 4.1 
1 89.3 
± 6.4 
81.1 
± 5.2 
82.1 
± 3.1 
84.2 
± 4.5 
 
 
 
PLGA 
(75:25) 
10 72.8 
± 5.5 
73.1 
± 4.3 
67.5 
± 4.2 
71.1 
± 3.2 
6 73.8 
± 5.3 
73.5 
± 2.2 
76.3 
± 3.7 
74.5 
± 1.5 
3 78.0 
± 6.5 
72.3 
± 8.9 
78.3 
± 5.4 
76.2 
± 3.4 
1 83.9 
± 9.0 
87.4 
± 4.8 
86.9 
± 2.9 
86.1  
± 1.9 
 
 
 
PLA 
10 41.9 
± 2.9 
44.3 
± 1.0 
38.9 
± 1.8 
41.7  
± 2.7 
6 46.6 
± 2.4 
48.4 
± 1.4 
51.9 
± 1.1 
48.9  
± 2.6 
3 65.7 
± 3.9 
63.2 
± 2.8 
60.9 
± 2.9 
63.3  
± 2.4 
1 84.6 
± 2.4 
87.6 
± 1.7 
88.0 
± 1.3 
6.70  
± 1.9 
 
Table 5.8 presents the results of one-way ANOVA with post hoc Tukey test for the inter 
day results (Table 5.7), with each polymeric nanoparticle type and concentration compared 
against each other. All polymers at all concentrations had cell viability readings 
statistically different to the control (PBS). Both PLGA (50:50) and PLA had significantly 
different cell viabilities compared to PLGA (75:25) for concentrations of 10, 6 and 3 
mg/mL; however there was no significant difference at low concentrations (1 mg/mL), 
possibly due to the amount of DOX loaded within the nanoparticles being too low to have 
a distinct cytotoxic effect. Overall, PLA had the most cytotoxic effect on the cells, with 
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cell viability being below 45 % after 24 h incubation with a concentration of dual drug 
loaded nanoparticles (10 mg/mL). 
 
Table 5.8. Statistical differences (p values) from the dose response experiments on CALU-
3 cells (red indicates statistical difference). 
 
Further experiments were run for 4, 8 and 24 h incubation time, at a concentration of 3 
mg/mL (Figure 5.15) and on consecutive days (with cells at different passage numbers). As 
the incubation time increased, so did the cytotoxic effect on the cells and this was seen for 
all 3 polymeric nanoparticle types.  
 
Figure 5.15. Cytotoxicity results at varying incubation times for PLGA (50:50), PLGA 
(75:25) and PLA electrosprayed particles loaded with both DOX and FA (3 mg/ml of 
??????????????????????/mL of DOX) on CALU-3 cells (n = 6; ± SD). 
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Polymer	  
	  
mg/	  
mL	  
PLGA	  (50:50)	   PLGA	  (75:25)	   PLA	  10	   6	   3	   1	   10	   6	   3	   1	   10	   6	   3	   1	  
PBS	   0.000	   0.000	   0.000	   0.000	   0.000	   0.000	   0.001	   0.000	   0.000	   0.000	   0.000	   0.000	  
	  
PLGA	  
(50:50)	  
10	   	   0.885	   0.000	   0.000	   0.000	   0.000	   0.000	   0.000	   0.750	   1.000	   0.000	   0.000	  6	   	   	   0.013	   0.000	   0.000	   0.000	   0.000	   0.000	   0.026	   1.000	   0.060	   0.000	  3	   	   	   	   0.000	   0.647	   0.073	   0.000	   0.000	   0.000	   0.001	   1.000	   0.000	  1	   	   	   	   	   0.000	   0.017	   0.985	   0.999	   0.000	   0.000	   0.000	   1.000	  
	  
PLGA	  
(75:25)	  
10	   	   	   	   	   	   0.993	   0.024	   0.000	   0.000	   0.000	   0.302	   0.000	  6	   	   	   	   	   	   	   0.373	   0.001	   0.000	   0.000	   0.017	   0.005	  3	   	   	   	   	   	   	   	   0.589	   0.000	   0.000	   0.000	   0.897	  1	   	   	   	   	   	   	   	   	   0.000	   0.000	   0.000	   1.000	  
	  
PLA	  
10	   	   	   	   	   	   	   	   	   	   0.220	   0.000	   0.000	  6	   	   	   	   	   	   	   	   	   	   	   0.005	   0.000	  3	   	   	   	   	   	   	   	   	   	   	   	   0.000	  1	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Table 5.9 shows data obtained from each separate day of the experiment, with the results 
being very similar, showing they are reproducible at different cell passages (p values all 
above 0.05). The statistical values for each incubation time for the average cell viability 
are presented in Table 5.10. After a 4 hour incubation no significant difference when 
compared to PBS was found in the cell viability, however after a 24 h incubation time 
there was a significant difference for all 3 types of polymeric nanoparticles (p value = 
0.000 for all 3 nanoparticle types). For an 8 h incubation time both PLGA (50:50) and 
(75:25) had significantly different cell viability values compared to PBS (p values = 0.001 
and 0.012 respectively); somehow surprisingly, cells incubated with PLA nanoparticles did 
not (p value = 0.191). This was surprising due to the PLA nanoparticles having the most 
cytotoxic effect after 24 hours, however the least after 8 hours.   
 
Table 5.9. Cell viability data for CALU-3 cells performed at different passage no; cells 
were incubated with electrosprayed nanoparticles loaded with DOX and FA (3 mg/ml of 
??????????????????????/mL of DOX) over 4, 8 and 24 hour incubation periods (n = 6; ± 
SD). 
 
Polymer Incubation 
time (h) 
Cell viability against PBS (%) [passage number] 
Day 1 
[30] 
Day 2 
[32] 
Day 3 
[33] 
Mean 
 
 
PLGA 
(50:50) 
4 94.9 
± 1.8 
88.3 
± 1.6 
93.5 
± 2.3 
92.3 
± 3.4 
8 84.3 
± 2.7 
80.6 
± 2.9 
80.5 
± 1.9 
81.8 
± 2.2 
24 67.9 
± 1.5 
62.9 
± 1.3 
64.4 
± 2.3 
65.1 
± 2.6 
 
 
PLGA 
(75:25) 
4 98.6 
± 2.9 
95.7 
± 2.6 
99.7 
± 1.6 
98.0 
± 2.1 
8 85.1 
± 3.4 
84.5 
± 2.9 
83.7 
± 1.3 
84.4 
± 0.7 
24 76.2 
± 3.1 
78.4 
± 3.0 
77.4 
± 1.70 
77.3 
± 1.1 
 
 
PLA 
4 98.8 
± 2.3 
95.7 
± 1.5 
96.8 
± 2.9 
97.1 
± 1.6 
8 86.4 
± 1.1 
89.2 
± 1.2 
88.4 
± 3.6 
88.0 
± 1.4 
24 66.3 
± 0.9 
62.4 
± 1.4 
63.5 
± 3.2 
64.1 
± 2.0 
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Experiments were only run up to 24 h because longer incubation time could lead to 
contamination, which can introduce artefacts in the cytotoxic effect measured. 
 
Table 5.10. Statistical significance (p values; ANOVA with Tukey post-test) from the 
incubation response experiments on CALU-3 cells (red indicates statistical difference), 
PBS value stayed the same for each incubation period. 
 
The cytotoxicity effect of nanoparticles was also tested on human bronchial epithelial cell 
line 16HBE, which was employed as a control for normal human cells as they do not 
overexpress folate receptors39 and therefore would allow comparison with the CALU-3 cell 
line in terms of target selectivity of the loaded nanoparticles.  
 
The cytotoxicity of particles loaded with both DOX and folic acid had no significant 
difference on the 16HBE cells at 10 mg/mL concentration when compared to PBS (p 
values 0.988, 0.213 and 0.997 respectively; Figure 5.16 and Table 5.11). However, they 
showed a significant difference in their cytotoxicity when compared to the corresponding 
particles loaded with only DOX (no folic acid), with p values = 0.000 for PLGA (50:50) 
and PLA and 0.006 for PLGA (75:25). Also, all nanoparticles loaded with DOX (no folic 
acid) showed significantly different cell viabilities compared to PBS (p values = 0.000 for 
all), which would suggest that folic acid might work as a protective agent for normal cells 
(16HBE), preventing nanoparticles from being uptaken.  
 
 Polymer PLGA (50:50) PLGA (75:25) PLA 
Polymer Incubation 
Time (h) 
24 8 4 24 8 4 24 8 4 
PBS 0.000 0.001 0.993 0.000 0.012 1.000 0.000 0.191 1.000 
 
PLGA 
(50:50) 
24  0.000 0.000 0.755 0.000 0.000 0.952 0.000 0.000 
8   0.068 0.001 0.998 0.008 0.000 0.558 0.020 
4    0.000 0.290 1.000 0.000 0.894 1.000 
 
PLGA 
(75:25) 
24     0.000 0.000 1.000 0.000 0.000 
8      0.056 0.000 0.961 0.115 
4       0.000 0.451 1.000 
 
PLA 
24        0.000 0.000 
8         0.649 
4          
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Figure 5.16. Cytotoxicity assay on 16HBE cells of loaded nanoparticles at 10 mg/mL (525 
??/mL of DOX). Free DOX base and salt at the same concentration as that loaded into 
nanoparticles were used as controls; Triton-X (T-X) was also used as a positive control at 
0.1 % v/v (n = 6; ± SD); incubation time 24 h. 
 
 
Table 5.11. Individual inter day data of cytotoxicity studies on 16HBE cells incubated with 
electrosprayed nanoparticles loaded with DOX and FA, 10 mg/mL of nanoparticles with 
???????/mL of DOX, for 24 h (n = 6; ± SD). 
020
4060
80100
120
PLGA(50:50) PLGA(75:25) PLA PLGA(50:50) PLGA(75:25) PLA DOXBase DOXSalt T-­‐XPBS Particles	  loaded	  with	  FA+	  DOX Particles	  loaded	  withDOX Controls
Cell	  via
bility	  a
gainst	  
PBS	  (%
)	  
Polymer Loaded 
with 
Cell viability against PBS (%) [passage number] 
Day 1 
[33] 
Day 2 
[35] 
Day 3 
[37] 
Mean 
 
PLGA 
(50:50) 
F+D 96.4 
± 0.1 
98.5 
± 1.2 
98.6 
± 1.6 
97.8 
± 1.2 
D 83.8 
± 1.1 
80.3 
± 1.9 
84.3 
± 1.2 
82.8 
± 2.2 
 
PLGA 
(75:25) 
F+D 91.4 
± 1.2 
92.2 
± 0.5 
90.6 
± 1.9 
91.4 
± 0.8 
D 80.4 
± 1.6 
79.7 
± 0.9 
79.0 
± 0.6 
79.7 
± 0.7 
 
PLA 
F+D 99.0 
± 1.9 
97.6 
± 1.8 
98.9 
± 1.4 
98.5 
± 0.8 
D 76.1 
± 1.5 
75.8 
± 1.2 
76.9 
± 1.3 
76.3 
± 0.6 
DOX Base 84.5 
± 0.6 
83.8 
± 1.2 
84.8 
± 0.9 
84.4 
± 0.5 
DOX Salt 54.1 
± 0.3 
53.8 
± 0.5 
52.9 
± 1.9 
53.6 
± 0.6 	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5.3.2. Cellular uptake  
To investigate the targeting properties of the FA-loaded nanoparticles, both CALU-3 and 
16HBE cells that were incubated for 24 h with nanoparticles loaded with both DOX and 
folic acid were studied using flow cytometry. Cells alone have a certain level of auto-
fluorescence that allows them to be detected without the need for labelling. Polymeric 
nanoparticles loaded with DOX only (no folic acid) were employed as controls.  
 
The CALU-3 cells that were incubated with nanoparticles loaded with both DOX and folic 
acid had a higher fluorescence than those cells incubated with nanoparticles loaded with 
DOX only - this was found for all three types of polymeric nanoparticles (Figures 5.17 to 
5.19). This is likely to be due to the folic acid targeting the cells and therefore leading to an 
increased uptake. Table 5.12 summarises the mean of the fluorescence intensity from the 
histograms and presents a breakdown of the average fluorescence detected in the CALU-3 
cells for each separate day (different cell passage number). For each sample it can be seen 
that the cells incubated with PLA nanoparticles (loaded with both DOX and folic acid) had 
the highest fluorescence, and that cells incubated with PLGA (75:25) nanoparticles had the 
lowest fluorescence.  
 
There is a significant difference between the fluorescence detected in the cells incubated 
with nanoparticles loaded with both DOX and folic acid compared to the CALU-3 cells 
incubated with their corresponding nanoparticles loaded with DOX only (p values = 0.000 
for all). There is no significant difference between the fluorescence detected in the cells 
that were incubated with DOX loaded nanoparticles (no folic acid) compared to that of the 
cells incubated without nanoparticles (p values = 1.000 for PLGA (50:50) and (75:25), 
0.994 for PLA) (Table 5.12). The results did not differ when run on different days 
confirming that the results are therefore reproducible under different cell passages. These 
results could be due to the lack of folic acid meaning that the nanoparticles were not 
targeted towards the cells and therefore uptake did not occur.  
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Table 5.12. Mean of relative fluorescence intensity (geo-means) for CALU-3 cells 
incubated for 24 h with polymeric nanoparticles loaded with both DOX and FA compared 
to those loaded with DOX only. CALU-3 cells alone were used as negative control; DOX 
salt used as a positive control (n = 6; ± SD). 
 
 
For the PLGA (50:50) DOX only loaded nanoparticles, 92.23 % of the gated cells were 
present in the population having a lower fluorescence (R2) compared to 5.42 % of the cells 
treated with nanoparticles loaded with DOX and folic acid (Table 5.13). This is also 
evident in the histograms presented in Figure 5.17 D, where the blue line representing cells 
incubated with DOX and folic acid loaded nanoparticles appears at higher fluorescence 
intensity compared to the cells incubated with DOX only loaded nanoparticles (orange).  
 
Polymer Loaded 
with 
Cell viability against PBS (%) [passage number] 
Day 1 
[34] 
Day 2 
[35] 
Day 3 
[37] 
Average 
 
PLGA 
(50:50) 
D 8.9 
± 2.4 
8.0 
± 1.4 
14.0 
± 1.1 
10.3 
± 3.2 
F+D 222.5 
± 10.1 
215.2 
± 8.6 
239.8 
± 6.680 
225.8 
± 12.6 
 
PLGA 
(75:25) 
D 8.2 
± 2.5 
8.5 
± 3.9 
6.6 
± 1.2 
7.8 
± 1.0 
F+D 246.5 
± 18.8 
197.9 
± 25.4 
191.2 
± 17.4 
211.9 
± 30.2 
 
PLA 
D 31.7 
± 1.9 
14.6 
± 2.1 
15.7 
± 1.1 
20.7 
±9.6 
F+D 313.4 
± 8.6 
344.6 
± 16.9 
299.4 
± 14.9 
319.1 
± 23.1 
Control (-ve) 3.9 
± 0.1 
3.9 
± 0.1 
3.9 
± 0.1 
3.9 
± 0.0 
Control (+ve) 323.6 
± 2.3 
311.9 
± 1.8 
317.6 
± 0.9 
317.7 
± 5.9 
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Figure 5.17. Flow cytometry data (histogram of fluorescence) for CALU-3 cells incubated 
for 24 h with of PLGA (50:50) nanoparticles; CALU-3 cells alone, as control  (A); PLGA 
(50:50) nanoparticles loaded with DOX (10 mg/mL of nanoparticles; ~???????????????
(B); PLGA (50:50) nanoparticles loaded with DOX and FA (10 mg/mL nanoparticles; 
~??????????????????????????????????????????????????????????????????????lines (D). 
 
 
 
 
Table 5.13. Geo-means for each gated area including percentages from the dot plot data 
gates in Figure 5.18: all cells minus debris (R1), lower fluorescence population (R2) and 
higher fluorescence population (R3). 
 
 
Gate 
(R) 
DOX + FA NPs DOX NPs 
% Gated % Total % Gated % Total 
1 100.00 92.24 100.00 93.44 
2 5.88 5.42 98.71 92.23 
3 93.77 86.50 0.92 0.86 
	  	   152	  
 
 
Figure 5.18. Flow cytometry dot plots, gated against control (R2) for CALU-3 cells 
incubated with PLGA (50:50) nanoparticles loaded with both FA and DOX (A), and with 
PLGA (50:50) nanoparticles loaded with DOX only (no FA) (B).  
 
 
For the PLGA (75:25) DOX loaded nanoparticles, 90.28 % of the gated cells were present 
in the population with lower fluorescence (R2) compared to 5.24 % of the cells incubated 
with nanoparticles loaded with both DOX and folic acid (Table 5.14). The higher 
fluorescence population (R3) however contains 82.80 % of the cells incubated with DOX 
and folic acid loaded nanoparticles and just 1.10 % of the DOX (no FA) loaded 
nanoparticles respectively, suggesting that the presence of folic acid has a considerable 
effect on the uptake process into the CALU-3 cells.  
 
 
A 
B 
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Figure 5.19. Flow cytometry data (histogram of fluorescence intensity) for CALU-3 cells 
incubated for 24 h with of PLGA (75:25) nanoparticles; CALU-3 cells alone, as control 
(A); PLGA (75:25) nanoparticles loaded with DOX (10 mg/mL of nanoparticles; ~500 
?????? ????? ????? ????? ???????? ?????????????? ??????? ????? ???? ???? ??? ???? ??????
nanoparticles; ~???????????????????????????????y of A (pink), B (orange) and C (blue) 
(D). 
 
 
 
Table 5.14. Geo-means for each gated area as percentage from the dot plot data gates in 
Figure 5.20: all cells minus debris (R1), lower fluorescence population (R2) and higher 
fluorescence population (R3). 
 
Gate 
(R) 
DOX + FA NPs DOX NPs 
% Gated % Total % Gated % Total 
1 100.00 88.52 100.00 91.69 
2 5.91 5.24 98.46 90.28 
3 93.54 82.80 1.20 1.10 
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Figure 5.20. Flow cytometry dot plots gated against control (R2) for CALU-3 cells 
incubated with PLGA (75:25) nanoparticles loaded with FA and DOX (A), and with PLGA 
(75:25) nanoparticles loaded with DOX only (no FA) (B).  
 
 
For the PLA DOX loaded nanoparticles, 86.36 % of the gated cells were present in the 
population corresponding to lower fluorescence (R2) compared to 4.18 % of the cells 
incubated with nanoparticles loaded with both DOX and folic acid (Table 5.15). The 
higher fluorescence population (R3) contains 88.86 % of the cells incubated with DOX and 
folic acid loaded nanoparticles and just 4.28 % of the cells incubated with DOX loaded 
nanoparticles, showing that more nanoparticles are taken into the CALU-3 cells when folic 
acid was present. This can be also seen in the histograms presented in Figure 5.21 D, 
where the blue line at high fluorescence represents the cells incubated with the 
nanoparticles loaded with both DOX and folic acid.   
 
A 
B 
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Figure 5.21. Flow cytometry data (fluorescence intensity histograms) for CALU-3 cells 
incubated for 24 h: CALU-3 cells alone, as control  (A); CALU-3 incubated with PLA 
nanoparticles loaded with DOX only (10 mg/mL of nanoparticles; ~????????????????????
CALU-3 incubated with PLA nanoparticles loaded with both DOX and FA (10 mg/mL 
nanoparticles; ~??????????????????????????????????????????????????????????????????????
histograms (D). 
 
 
Table 5.15. Geo-means for each gated area including percentages from the dot plot data 
gates in Figure 5.22: all cells minus debris (R1), lower fluorescence population (R2) and 
higher fluorescence population (R3). 
 
 
 
Gate 
(R) 
DOX + FA NPs DOX NPs 
% Gated % Total % Gated % Total 
1 100.00 93.28 100.00 91.30 
2 4.48 4.18 94.59 86.36 
3 95.26 88.86 4.69 4.28 
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Figure 5.22. Flow cytometry dot plots, gated against control (R2) for CALU-3 cells 
incubated with PLA nanoparticles loaded with FA and DOX (A), and with PLA 
nanoparticles loaded with DOX only (no FA) (B).  
 
 
The dot plots for the cells incubated with all three types of nanoparticles showed similar 
data; after gating out the control two populations were visible. The population for the cells 
incubated with nanoparticles loaded with folic acid had higher fluorescence and was 
predominant, while the major population for the cells incubated with nanoparticles without 
folic acid had lower fluorescence (Figures 5.18, 5.20 and 5.22). This is also confirmed by 
the geo-mean values (Tables 5.13 – 5.15); gate 2 (R2) shows that the population with 
lower fluorescence is larger for the cells incubated with nanoparticles and no folic acid 
compared to the cells incubated with folic acid targeted nanoparticles. Totals do not add up 
to 100 % exactly due to gating (some cells can be left out when gating from controls).  
 
Overall, the flow cytometry data supports the conclusions from the MTT assays 
(summarised in Figure 5.14); the cells containing the highest fluorescence were those 
A 
B 
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incubated with PLA loaded nanoparticles, which also had the lowest cell viability from the 
MTT assay results. Among the types of polymers tested, PLGA (75:25) demonstrated the 
highest cell viability after 24 h nanoparticle incubation and the lowest fluorescence 
intensity (least uptake into CALU-3 cells) value measured by flow cytometry (Table 5.12). 
 
16HBE cell cellular uptake  
A similar behaviour was observed for all three types of polymeric nanoparticles when 
16HBE cells were used for incubation; the cells incubated with DOX-loaded nanoparticles 
(no FA) had higher fluorescence than those loaded with both DOX and folic acid (Table 
5.16 and Figures 5.23 - 5.25).  
 
Table 5.16. Geo-mean (mean of fluorescence intensity) for 16HBE cells incubated with 
polymeric nanoparticles loaded with DOX and FA compared to those loaded with DOX 
only (no FA); 16HBE cells alone as -ve control and DOX salt as +ve (n = 6; ± SD).  
 
Polymer Loaded 
with 
Geo-Mean [passage number] 
Day 1 
[34] 
Day 2 
[36] 
Day 3 
[38] 
Mean 
 
PLGA 
(50:50) 
D 8.0 
± 0.1 
6.4 
± 0.1 
6.3 
± 0.1 
6.9 
± 0.9 
F+D 3.4 
± 0.1 
3.2 
± 0.1 
3.3 
± 0.2 
3.3 
± 0.1 
 
PLGA 
(75:25) 
D 8.2 
± 0.1 
8.0 
± 0.0 
8.3 
± 0.1 
8.1 
± 0.2 
F+D 3.4 
± 0.1 
3.3 
± 0.2 
3.4 
± 0.1 
3.4 
± 0.1 
 
PLA 
D 6.7 
± 0.1 
6.4 
± 0.1 
6.6 
± 0.1 
6.6 
± 0.1 
F+D 3.3 
± 0.2 
3.1 
± 0.1 
3.2 
± 0.3 
3.2 
± 0.1 
Control (-ve) 2.9 
± 0.2 
2.6 
± 0.1 
2.7 
± 0.1 
2.7 
± 0.1 
Control (+ve) 320.7 
± 4.4 
341.2 
± 5.2 
333.2 
± 1.2 
331.7 
± 10.3 
 
 
 
 
	  	   158	  
 
Figure 5.23. Flow cytometry data (histogram of fluorescence intensity) for 16HBE cells 
incubated for 24 h: 16HBE cells alone, as control (A); 16HBE cells incubated with PLGA 
(50:50) nanoparticles loaded with DOX (10 mg/mL of nanoparticles; ~???????????????
(B); 16HBE cells incubated with PLGA (50:50) nanoparticles loaded with DOX and FA 
(10 mg/mL nanoparticles; ~??????????????? ??????????histogram overlay of A (pink), B 
(orange) and C (blue) (D). 
 
 
The average values of the fluorescence intensity (Table 5.16) showed that there is a 
statistical difference between the positive control and all nanoparticle treatments (p value = 
0.000 for all). There was no statistical difference between the cells alone and those 
incubated with DOX and folic acid loaded nanoparticles or DOX loaded nanoparticles. A 
higher uptake of the nanoparticles loaded with DOX alone into the 16HBE cells compared 
to those loaded with both DOX and folic acid (Figure 5.16) supports also the cytotoxicity 
data on normal lung cells obtained from the MTT assays.  
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Figure 5.24. Flow cytometry data (histogram of fluorescence intensity) for 16HBE cells 
incubated for 24 h: 16HBE cells alone, as control (A); 16HBE cells incubated with PLGA 
(75:25) nanoparticles loaded with DOX (10 mg/mL of nanoparticles; ~???????????????
(B); 16HBE cells incubated with PLGA (75:25) nanoparticles loaded with DOX and FA 
(10 mg/mL nanoparticles; ~??????????????? ??????????histogram overlay of A (pink), B 
(orange) and C (blue) (D). 
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Figure 5.25. Flow cytometry data (histogram of fluorescence) for 16HBE cells incubated 
for 24 h with of PLA nanoparticles; 16HBE cells alone, as control (A); 16HBE cells 
incubated with PLA nanoparticles loaded with DOX (10 mg/mL of nanoparticles; ~500 
??????????? ?????16HBE cells incubated with PLA nanoparticles loaded with DOX and 
FA (10 mg/mL nanoparticles; ~?????????????????????????histogram overlay of A (pink), 
B (orange) and C (blue) (D). 
 
 
5.3.3. Investigations of cellular uptake using confocal microscopy  
The uptake of DOX into cells was visualised using both confocal and fluorescent 
microscopy. Cell nuclei were stained with Hoechst 33342 and then visualised using DAPI 
(405 nm) channel, which was overlaid then with Rhod (543 nm) channel to visualise the 
loaded DOX. However, the cell nuclei were also detected in the Rhod channel so the 
overlaid image was not very clear, though accumulations of the red DOX loaded 
nanoparticles can be still be seen (Figure 5.26); they appear to be localised around the cells, 
suggesting targeting, which is backed up later in Figure 5.27. 
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Figure 5.26. Fluorescent micrographs showing CALU-3 cells after 2 h incubation with 
nanoparticles loaded with both DOX and FA (overlaid images of stained nuclei visualised 
with DAPI 405 nm and DOX nanoparticles visualised with Rhod 543 nm): PLGA (50:50) 
(A); PLGA (75:25) (B); and, PLA (C). Scale bar represents 90 µm.  
 
The same can be observed in the confocal images presented in Figure 5.27, with Figure 
5.27-C2 showing CALU-3 cells incubated with DOX and folic acid loaded PLA 
nanoparticles; though the nuclear stain was picked up in both channels, particles can be 
seen along the cellular membrane (red arrow) around the edge of the overlay images (C).  
 
 
Figure 5.27. Confocal micrographs showing cellular uptake (CALU-3 cells; 2 h 
incubation) of PLA nanoparticles loaded with DOX and FA, visualised using DAPI 405 nm 
(A) for cell nuclei, Rhod 543 nm (B) for DOX; and, an overlay (C). The images are 
presented at two different magnifications: 20X (1) and 63X (2), with the arrows indicating 
the presence of nanoparticle agglomerates. Scale bar equal to 50 µm (1) and 20 µm (2). 
B A C 
A1 
C2 
B1 C1 
B2 A2 
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This was seen for all three polymeric nanoparticle types (images of PLGA (50:50) and 
(75:25) nanoparticles presented in Appendix E). Under the X63 lens (2) red colour 
associated with DOX can be seen along the edges of the cells and starting to enter into 
those cells at the edges of the monolayer (white arrow).  
 
The nanoparticles were not expected to have been taken up into the cells yet as the 
incubation with nanoparticles was performed in this case for only 2 h (the cytotoxicity 
studies at 4 h incubation showed minimal cell death, suggesting that the cells need longer 
incubation times for significant uptake).  
 
5.3.4. Live cell imaging 
For confocal microscopy the cells had to be fixed and therefore only a set incubation time 
could be investigated, however the live cell imaging technique allowed monitoring DOX 
cell uptake in real time (though limited to about 6 h due to photo bleaching). Cells 
incubated with nanoparticles loaded with both DOX and folic acid were investigated over 
24 h and it was observed that the samples photo bleached under the experimental 
conditions (excitation 546/12 nm; emission 575 – 640 nm; 15 min interval). 
 
Cells incubated with a nuclei stain were also visualised as a control to confirm the presence 
of cells because when CALU-3 cells split and divide sometime cell debris can be left 
behind (Figure 5.28). 
 
Figure 5.28. Live cell imaging snapshots displaying CALU-3 cells stained with Hoechst 
33342 (A) and DAPI (B) and visualised under live cell imaging (3 h incubation). 
 
A	   B	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 Figure 5.29. Micrographs showing the CALU-3 cells following incubation with PLGA 
(50:50) nanoparticles loaded with both DOX and FA at different time points (h:min). 
 
After 3 h it was seen that the DOX has started entering the cells when incubated with 
PLGA (50:50) and PLA nanoparticles (Figures 5.29 and 5.31 respectively), however the 
PLGA (75:25) nanoparticles took longer to be taken up into the cells (Figure 5.30). At the 
5 h time point, for cells incubated with PLGA (50:50) it was seen that DOX localises 
firstly around the edge of each cell and is being taken up considerably (cells fully red due 
to uptaken DOX) over a 6 h period (Figure 5.29). This could also be seen in Figure 5.30, 
where the PLGA (75:25) nanoparticles do not appear to have got into the cells at 3 h but by 
4 – 5 h many cells are red and as is the outline of the others, suggesting that DOX 
contained in the nanoparticles is getting ready to go inside all cells. After 4 h incubation 
with the PLA loaded nanoparticles, the majority of cells are surrounded by DOX 
(associated with the surrounding red colour), and all cells appear to contain DOX after 6 h.  
 
3:00	  
6:00	  5:00	  
4:00	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  Figure 5.30. Micrographs showing the CALU-3 cells following incubation with PLGA 
(75:25) nanoparticles loaded with both DOX and FA at different time points (h:min). 
 
Figure 5.31. Micrographs showing the CALU-3 cells following incubation with PLA 
nanoparticles loaded with both DOX and FA at different time points (h:min). 
3:00	   4:00	  
6:00	  5:00	  
4:00	  3:00	  
5:00	   6:00	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The live cell images monitoring incubation of CALU-3 cells with different types of 
nanoparticles showed that after 6 h DOX was taken up into all cells incubated with PLA 
nanoparticles, while those incubated with PLGA (50:50) and (75:25) nanoparticles had 
DOX all around their outer walls. Looking at the release profiles in Chapter 4 (Figures 
4.16 – 4.18), optimal cellular uptake would be within the first 3 – 6 hours, during the burst 
release of DOX from the nanoparticles. The live cell images (Figures 5.29 – 5.31) show 
visually that the nanoparticles are being taken up within this period, mainly visible from 4 
hours at which the release of DOX is approximately 30 % for PLGA (50:50) and PLGA 
(75:25). PLA nanoparticles at 4 hours had only released approximately 20 % of DOX, 
showing their increased promise to be the more ideal delivery system.  	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5.4. Conclusions 
Cytotoxicity studies demonstrated that materials alone (unloaded polymeric nanoparticles 
and folic acid) do not have a cytotoxic effect on the CALU-3 cells at concentrations up to 
10 mg/mL.  
 
Nanoparticles with both DOX and folic acid loaded in combination did have a cytotoxic 
effect on CALU-3 cells, as expected, with increasing nanoparticle concentration and/or 
incubation time leading to a decrease in cell viability. The PLA nanoparticles loaded with 
both DOX and FA had the largest cytotoxic effect, with PLGA (75:25) ones causing the 
least cell death (approximately 42 and 70 % respectively at a concentration of 10 mg/mL 
and 24 h incubation time). The PLA nanoparticles had the highest amount of folic acid 
incorporated within them and this could be the reason they had the most cytotoxic effect 
due to the higher targeting agent allowing them to reach the cells.  
 
Nanoparticles without folic acid (DOX only) did show significantly lower cytotoxic effect 
in CALU-3 cells compared to nanoparticles loaded with both DOX and FA, suggesting 
that the folic acid could be working as a targeting agent towards the folate receptors known 
to be overexpressed on the CALU-3 cells. In contrast, on normal human lung cells 
(16HBE), the nanoparticles containing FA did not show a marked cytotoxic effect (as 
expected due to the presence of DOX), while the nanoparticles loaded with just DOX (no 
FA) did have an effect. It is therefore suggested that the folic acid could be acting as a 
protective agent against uptake of nanoparticles or the DOX contained therein by the 
16HBE cells. 
 
The flow cytometry results supported the cytotoxicity data on both CALU-3 and 16HBE 
cells, showing that the highest fluorescence was seen in the CALU-3 cells incubated with 
FA-containing nanoparticles (the higher fluorescence population being approximately 20 
times larger for those cells incubated with nanoparticles loaded with both DOX and folic 
acid, compared to those without folic acid). 16HBE cells were shown to have a similar 
fluorescence to that of the control (cells alone) indicating there was no enhanced uptake.  
 
Live cell imaging showed that the uptake of DOX from the nanoparticles considered in this 
study was first noticeable at 4 h and was found to increase considerably afterwards (photo 
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bleaching limited the duration of experiments to 6 h). Cells could be seen to become red 
around the walls first and then gradually throughout, clearly showing the progression of 
the uptake of DOX. The cells incubated with PLA nanoparticles had the higher 
nanoparticle uptake (highest intensity of red as appreciated visually) after 6 h, will all the 
cells having DOX inside them. For the cells incubated with either PLGA (50:50) or PLGA 
(75:25) nanoparticles,	   the DOX concentration in the cells (as appreciated visually by the 
intensity of the red colour) was not as intense as in the case of the PLA nanoparticles.  
 
The results presented in this chapter would suggest that the polymer with the most promise 
for the treatment of lung cancer when using folic acid as a targeting agent is PLA. When 
formulated as electrosprayed nanoparticles loaded with both DOX and folic acid, PLA 
demonstrated higher cytotoxicity (lowest cell viability after 24 h incubation), higher 
cellular uptake (as determined by flow cytometry) and faster/more intense delivery of 
DOX (as observed by live cell imaging) compared to its PLGA based congeners. The folic 
acid content may have been highest however the DOX content in the PLA nanoparticles 
was the lowest, yet they still resulted in the highest cytotoxicity.   
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6. General discussion and conclusions 
 
 
There is a need for targeted cancer chemotherapies that are more selective than the current 
treatments; this is because they should have fewer side effects, therefore being more 
desirable to patients. Biopolymers such as PLA and PLGA are biocompatible and 
biodegradable and have been shown to have excellent characteristics that make them good 
carriers for anti-cancer drug delivery applications. Formulating such biomaterials into 
nanocarriers, loaded with required actives, which also have selective targeting properties 
requires convenient and versatile fabrication techniques. EHDA is a one-step method that 
has the potential to produce successful drug delivery systems with incorporated targeting 
agents.  
 
In this work, the main process parameters (flow rate, applied voltage, collection distance 
and polymeric concentration) for EHDA fabrication of nanocarriers based on PLA and 
PLGA of different composition were investigated and optimised. As a result of the 
optimisation studies, nanocarriers (average size 98 ± 8 nm) loaded with anti-tumor drug 
doxorubicin and folic acid as targeting agent were produced. 
 
The collection distance was shown to have an important effect on the size, monodispersity 
and stability of nanoparticles prepared from all materials considered, with the optimum 
(for the solvents tested) being around 15 cm at an applied voltage between 9.1 – 9.4 kV 
and a polymer concentration of 5 % w/v. It was found that particle diameter decreased with 
increasing collection distance, with jet-cone instability manifested at collection distances 
approaching 20 cm, which caused a decrease in size.  
 
Increasing the flow rate was shown to increase the particle diameter, however the effect 
was not as significant as in the case of collection distance. The solvent volatility was also 
shown to have an impact on the particle diameter, with a decrease in particle size observed 
when changing from DMSO to the more volatile ACN and DCM. 
  
The successful incorporation of both folic acid and DOX within PLA and PLGA polymeric 
nanoparticles was evidenced by HPLC and FTIR. The observed changes in the zeta 
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potential value after the addition of folic acid suggests that at least some of it is present on 
the surface of the nanoparticles.  
 
Release studies of DOX from loaded nanoparticles evidenced considerable burst release in 
the first day following by sustained release of the remaining drug for almost one week. In 
contrast, the release of folic acid was relatively rapid and supports the hypothesis that a 
large amount of the folic acid was distributed on the surface of the nanoparticles.  
 
Though almost completely released within 8 h, the folic acid succeeded however in 
imparting the desired tumor targeting characteristics to loaded nanoparticles as proven by 
in vitro experiments using a positive folate expressing cell line (CALU-3) against a normal 
lung cell line (16HBE) that does not overexpress folate receptors. The effect is likely the 
result of a combination between the selective uptake of DOX loaded nanoparticles into 
tumour cells (observed to take place within several hours) and the competing process of 
FA release from the nanoparticles. 
 
The cell viability of CALU-3 cells was found to be significantly lower following 
incubation with nanoparticles loaded with both DOX and folic acid compared to that of 
16HBE cells. The polymeric nanoparticles and folic acid were proved to have no cytotoxic 
effect.  
 
Interestingly, a significant difference was found between the nanoparticles loaded with 
both DOX and folic acid and those loaded with just DOX (no FA), suggesting that the folic 
acid may play a protective role in normal cells (16HBE). The folic acid loaded 
nanoparticles were shown to have a significantly higher uptake into cancer cells (CALU-3) 
compared to the nanoparticles without folic acid, with live cell imaging showing steady 
uptake over 6 hours. 
 
In conclusion, EHDA can be conveniently employed as a method to effectively produce a 
targeted nanoparticulate system containing folic acid for the selective delivery of 
anticancer actives to tumour cells overexpressing folate receptors, in a simple one-step 
procedure. PLA loaded nanoparticles showed the most promise for targeted lung cancer 
treatment.  
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To take this work forward, a multiplex needle system could be employed to increase the 
production/yield of nanoparticles, re-optimisation would then be required due to possible 
interference between the electric fields of the multiple needles. However research has 
shown that this is a viable method for scaling up the yield of particles without 
compromising the final product.25–27 Further studies of the nanoparticle cell uptake process 
in competition with the release of folic acid would need to be carried out. Nanocapsules 
with FA loaded in the core (or coated on the surface only) could be produced using a co-
axial system, and the results would allow optimisation of the FA distribution within the 
nanoparticulate carrier for an optimum balance. 
  
The effect of DOX and FA loaded nanoparticles on other cancer cells lines known to 
overexpress folate receptors such as mouth epidermal carcinoma cells (KB) and cervical 
cancer calls (HeLa) should be investigated as well; other cell lines that do not overexpress 
these receptors (such as breast cancer cell line MCF7) could also be used as negative 
controls to further explore the selectivity of the proposed solution. For the cell viability 
tests, the incubation time with nanoparticles could be increased (in 24 h increments, for up 
to one week) to examine the long term effects on the cell lines studied. In vivo experiments 
could be considered next using subcutaneously implanted carcinomas in mice.  
 
As to my knowledge electrospraying has not been used to attach antibodies onto 
nanoparticles; however with optimisation and possibly a co-axial setup it could be a viable 
option. However the expenditure and stability issues that would come with using 
antibodies can be avoided when using folic acid to target folate receptors, which is cheap 
and has been proven to be able to be incorporated within nanoparticles with ease when 
using electrospraying. As a one-step method it is a lot easier than other work involving 
covalently bound folic acid to nanoparticles.  
 
 
	  	   177	  
7. Appendices 
 
Appendix A – PLA synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram showing the synthesis of PLA with different molecular weight.  	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Appendix B – Optical micrographs 
 
  A	  
B	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Optical micrographs for electrosprayed unloaded PLGA (50:50) particles at varying 
CDs: 5 cm (A), 10 cm (B), 15 cm (C) and 20 cm (D). 
C	  
D	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Appendix C – FTIR spectra	  
 
 
 
C-1. FTIR spectra of pure PLGA (50:50), DOX, FA and PLGA (50:50) electrosprayed 
loaded nanoparticles.  
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C-2. FTIR spectra of pure PLGA (75:25), DOX, FA and PLGA (75:25) electrosprayed 
loaded nanoparticles.  
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 C-3. FTIR spectra of pure PLA, DOX, FA and PLA electrosprayed loaded nanoparticles.  
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Appendix D – FA and DOX calibration 
curves 
 
 
 
D-1. FA calibration ??????????????????????????????????????????????????????????????????????? 
 
 
 
D-2. FA calibration curve ran fresh and then 24 hours later after being stored at room 
??????????????????????????????????????????????? 
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D-3. FA calibration curve ran fresh and then 48 hours later after being stored in the fridge 
?????????????????????????????????? 
 
 
  
D-4. DOX base calibration curve ran fresh and 24 hours later after being stored at room 
temperature or ????????????????????????????????????????? 	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D-5. Close up of the DOX calibration curve, looking at the lower end of the concentration 
range to check linearity. 	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Appendix E – Confocal micrographs 
 
 
 
E-1. Confocal micrographs showing cellular uptake of PLGA (50:50) nanoparticles (2 h 
incubation) loaded with DOX and FA, visualised using DAPI 405 nm (A) for cell nuclei, 
Rhod 543 nm (B) for DOX and an overlay (C), at 20X (1) and 63X (2). 
 
 
 
 
 
 
 
 
 
C1 A1 
A2 B2 C2 
B1 
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E-2. Confocal micrographs showing cellular uptake of PLGA (7525) nanoparticles (2 h 
incubation) loaded with DOX and FA, visualised using DAPI 405 nm (A) for cell nuclei, 
Rhod 543 nm (B) for DOX and an overlay (C), at 20X (1) and 63X (2). 
 
  
A1 B1 C1 
A2 B2 C2 
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Appendix F – Flow cytometry gates 
 
 
 
F-1. Standard gates used on flow cytometer from a control of the cells alone, to eliminate 
debris and agglomerates: CALU-3 cells (A) and 16HBE cells (B).  
 
 
F-2. Gate used for dot plots of fluorescence of CALU-3 cells alone (not incubated with any 
nanoparticles).  	  
A B 
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